A Dark Vector Cognition product
10-K comparison

Healthpeak Properties (DOC) 10-K risk factor changes: FY2023 vs FY2022

The 2023-12-31 10-K against the 2022-12-31 one, compared heading by heading and sentence by sentence.

Item 1A118 rewritten237 added43 removed289 unchanged

All filing items1,707 rewritten876 added780 removed1,784 unchanged

Read the changesGo to Item 1A

Healthpeak Properties Form 10-K, every itemFY2023, filed 9 February 2024, against FY2022, filed 8 February 2023FY2023 on sec.govFY2022 on sec.govRead this filing

Summary

counted, not written

New Item 1A headings (21)

  1. We may be required to recognize reserves, allowances, credit losses, or impairment charges.
  2. ESG and sustainability commitments and requirements, as well as stakeholder expectations, may impose additional costs and expose us to new risks.
  3. The market price and trading volume of our common stock may be volatile.
  4. Our taxable REIT subsidiaries (TRSs) may be subject to corporate level tax.
  5. The tax imposed on any net income from “prohibited transactions” may limit our ability to engage in transactions which would be treated as sales for federal income tax purposes.
  6. Tax protection agreements may limit our ability to sell or otherwise dispose of certain properties and may require us to maintain certain debt levels that otherwise would not be required to operate our business.
  7. Conflicts of interest may exist or could arise in the future between the interests of our stockholders and the interests of holders of Healthpeak OP common units, which may impede business decisions that could benefit our stockholders.
  8. Certain provisions in the operating agreement of Healthpeak OP or other agreements may delay or prevent unsolicited acquisitions of us or certain other transactions.
  9. An adverse outcome in any litigation or other legal proceedings relating to the Merger Agreement, or the transactions contemplated thereby, could have a material adverse impact on our business and our ability to consummate the transactions contemplated by the Merger Agreement.
  10. The Exchange Ratio is fixed and will not be adjusted in the event of any change in the stock or share prices, respectively, of either us or Physicians Realty Trust.
  11. Our stockholders will be significantly diluted by the Mergers.
  12. The Combined Company expects to incur substantial expenses related to the Mergers.
  13. Following the Mergers, the Combined Company may be unable to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame.
  14. Following the Mergers and the transactions contemplated by the Merger Agreement, the Combined Company may be unable to retain key employees.
  15. The Mergers will result in changes to the board of directors of the Combined Company that may affect the strategy of the Combined Company as compared to that of the Company and Physicians Realty Trust individually.
  16. The future results of the Combined Company will suffer if the Combined Company does not effectively manage its operations following the Mergers and the transactions contemplated by the Merger Agreement.
  17. The trading price of shares of the Combined Company common stock following the Mergers may be affected by factors different from those affecting the price of shares of our common stock before the Mergers.
  18. Counterparties to certain significant agreements with Physicians Realty Trust may exercise contractual rights under such agreements in connection with the Mergers, including in certain cases the right to acquire properties owned by Physicians Realty Trust.
  19. The Combined Company’s anticipated level of indebtedness will increase upon completion of the Mergers and may increase the related risks Healthpeak currently faces.
  20. We may incur adverse tax consequences if Physicians Realty Trust has failed to qualify as a REIT for U.S. federal income tax purposes.
  21. The market price of shares of the Combined Company common stock may decline as a result of the Mergers and the transactions contemplated by the Merger Agreement.

Removed Item 1A headings (1)

  1. The section below discusses the most significant risk factors that may materially adversely affect our business, results of operations, and financial condition.
Reworded Item 1A headings (9)
  1. We may be negatively impacted by macroeconomic trends, including rising inflation and interest rates, increased [added: construction and] labor costs, and historically low unemployment.
  2. Our [removed: life science] [added: lab] tenants face significant regulation, funding requirements, and uncertainty.
  3. Decreases in our tenants’, operators’, or borrowers’ revenues, or increases in their expenses, [added: or other factors adversely affecting their ability to borrow money,] could affect their ability to meet their financial and other contractual obligations to us.
  4. The illiquidity of our real estate investments may [removed: prohibit] [added: prevent] us from timely responding to economic or investment performance changes.
  5. The hospitals on whose campuses our [removed: MOBs] [added: outpatient medical buildings] are located and their affiliated healthcare systems could fail to remain competitive or financially viable, which could adversely impact their ability to attract physicians and physician groups to our [removed: MOBs] [added: outpatient medical buildings] and our other properties that serve the healthcare industry.
  6. [removed: The] [added: Human capital risks, including the] loss or limited availability of our key [removed: personnel] [added: personnel,] could disrupt or impair our operations.
  7. Volatility, disruption, or uncertainty in the financial markets may impair our ability to raise capital, obtain new financing or refinance existing obligations, and fund [removed: real estate] [added: acquisition] and development activities.
  8. Increased borrowing costs could materially adversely impact our ability to refinance existing debt, sell [removed: properties] [added: properties,] and conduct [removed: acquisition, investment, and development activities, and could cause our stock price to decline.][added: investment activities.]
  9. Our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs could subject us [added: or our operators] to disruptive government and financial [removed: audits and investigations, regulatory] [added: audits,] enforcement actions, [removed: civil litigation,] and [removed: other claims, penalties, and liabilities.][added: recovery activity.]

A heading is new when no FY2022 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.

Sentences by item

24 items, with every count and a link to each item that changed

Underlined words on a shaded ground are new in FY2023; struck-through words were in FY2022. Sentences that are wholly new or wholly gone are labelled rather than marked.

Item 1A. Risk Factors

118 rewritten, 237 added, 43 removed, 289 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

The section below discusses the [removed: most significant] risk factors that may materially adversely affect our business, results of operations, and financial [removed: condition.][added: condition.]

Rewritten

- risks related to the regulatory environment; [removed: and]

Rewritten

- risks related to tax, including REIT-related risks, and [added: related to] our jurisdiction of [removed: incorporation.][added: incorporation and our structure as an UPREIT;]

Rewritten

We may be negatively impacted by macroeconomic trends, including rising inflation and interest rates, increased [added: construction and] labor costs, and historically low unemployment.

Rewritten

Many of our costs, including labor costs, [removed: costs of] construction [removed: materials, interest,] [added: costs,] utilities, and other operating [added: and administrative] costs, have been, and may continue to be, affected by inflation and price volatility.

Rewritten

In addition, interest rates rose substantially in 2022 and [added: 2023 and] may continue to [removed: rise.][added: rise and remain elevated for the foreseeable future.]

Rewritten

Increased interest rates have caused, and may continue to cause, [added: unfavorable financing terms and] increased interest costs for variable rate debt and new debt.

Rewritten

We may not be able to offset additional costs caused by inflation, increased interest [removed: rates] [added: rates,] or other macroeconomic trends by passing them through, or increasing the rates we charge, to tenants and residents.

Rewritten

These increased costs may [added: hinder our ability to execute on accretive acquisitions or otherwise] adversely affect our business, results of operations, and financial condition.

Rewritten

[removed: In addition,] [added: Furthermore,] rising labor costs and personnel shortages have increased, and may continue to increase, the cost of our, or our tenants’, operators’, and borrowers’, workforce.

Rewritten

Decreases in our tenants’, operators’, or borrowers’ revenues, or increases in their expenses, [added: or other factors adversely affecting their ability to borrow money,] could affect their ability to meet their financial and other contractual obligations to us.

Rewritten

Occupancy levels at, and rental income from, our [added: outpatient] medical [removed: office] and senior housing properties depend on our ability and the ability of our tenants, operators, and borrowers to compete with respect to (i) the quality of care provided, (ii) reputation, (iii) price, (iv) the range of services offered, (v) the physical appearance of a property, (vi) family preference, (vii) referral sources, and [removed: (xiii)] [added: (viii)] location.

Rewritten

In addition, our [added: outpatient] medical [removed: office] and senior housing tenants, operators, and borrowers compete with certain companies that have superior resources and attributes and/or provide similar healthcare services or alternatives such as home health agencies, telemedicine, life care at home, community-based service programs, retirement communities, and convalescent centers.

Rewritten

A shortage of care givers or other trained personnel, union [removed: activities,] [added: activities (including strikes, labor slowdowns, or contract negotiations),] wage laws, or general inflationary pressures on wages may require our tenants, operators, and borrowers to enhance pay and benefits packages, or to use more expensive contract personnel, and they may be unable to offset these added costs by increasing the rates charged to residents or patients.

Rewritten

An inability to attract and retain qualified personnel, including personnel possessing the expertise needed to operate in the life science, [removed: medical office,] [added: outpatient medical,] and senior housing sectors, could negatively impact the ability of our tenants, operators, and borrowers to meet their obligations to us.

Rewritten

Although we generally have the right under specified circumstances to terminate a lease, evict a tenant or terminate [removed: our] [added: an] operator, [removed: or] demand immediate repayment of outstanding loan amounts or other obligations to us, [added: or draw on a letter of credit,] we may be unable to enforce these rights or we may determine not to do so if we believe that doing so would be more detrimental than alternative approaches.

Rewritten

A downturn in our tenants’, operators’, or borrowers’ businesses [added: has led, and] could [removed: lead] [added: in the future lead,] to voluntary or involuntary bankruptcy or similar insolvency proceedings, including assignment for the benefit of creditors, liquidation, or winding-up.

Rewritten

Bankruptcy and insolvency laws afford certain rights to a defaulting tenant, operator, or borrower that has filed for bankruptcy or reorganization that [removed: may] [added: has, and in the future may,] render certain of our remedies unenforceable or, at the least, delay our ability to pursue such remedies and realize any related recoveries.

Rewritten

[removed: If] [added: When] a debtor [removed: were to reject] [added: rejects] its leases with us, obligations under such rejected leases [removed: would] cease.

Rewritten

The claim against the rejecting debtor for remaining rental payments due under the lease [removed: would be] [added: is] an unsecured [removed: claim, which would be] [added: claim] limited by the statutory cap set forth in the U.S. Bankruptcy Code.

Rewritten

Furthermore, the automatic stay provisions of the U.S. Bankruptcy Code [removed: would] preclude us from enforcing our remedies unless we first obtain relief from the court having jurisdiction over the bankruptcy case.

Rewritten

This [removed: would] effectively [removed: limit] [added: limits] or [removed: delay] [added: delays] our ability to collect unpaid rent or interest payments, and we may ultimately not receive any payment at all.

Rewritten

In addition, we [removed: would likely be] [added: have been, and may again be,] required to fund certain expenses and obligations (e.g., real estate taxes, insurance, debt costs, and maintenance expenses) to preserve the value of our properties, avoid the imposition of liens on our properties, or transition our properties to a new tenant or operator.

Rewritten

A downturn or slowdown in this [removed: sector, such as occurred during the Covid pandemic,] [added: sector] would have a greater adverse impact on our business than if we had investments across multiple sectors, and could negatively impact the ability of our tenants, operators, and borrowers to meet their obligations to us, as well as the ability to maintain historical rental and occupancy rates, which could have a material adverse effect on our business, results of operations, and financial condition.

Rewritten

The illiquidity of our real estate investments may [removed: prohibit] [added: prevent] us from timely responding to economic or investment performance changes.

Rewritten

In addition, infrastructure improvements for [removed: life science] [added: lab] properties typically are significantly more expensive than improvements to other property types due to the highly specialized nature of the properties and the greater lease square footage often required by [removed: life science] [added: lab] tenants.

Rewritten

Therefore, we may incur substantial expenditures to modify a [removed: life science] [added: lab] property and experience delays before we are able to secure a new or replacement tenant or operator or to accommodate multiple tenants or operators, which may have a material adverse effect on our business, results of operations, and financial condition.

Rewritten

- other factors over which we have limited or no control, including: (i) changes in market and economic conditions; (ii) natural disasters and other catastrophic [removed: events;] [added: events or physical climate risks, such as wildfires, earthquakes, and wind storms;] (iii) [removed: health crises] [added: pandemics] or other [removed: pandemics;] [added: health crises;] (iv) labor conditions, including a labor shortage or work stoppage; (v) shortages of construction materials; (vi) environmental conditions; or (vii) civil unrest and acts of war or terrorism.

Rewritten

In addition, changes in federal, state, and local legislation and regulation [removed: on] [added: relating to] climate change could require [added: (i)] increased capital expenditures to improve the energy efficiency or resiliency of our existing properties and increase the costs of new developments [added: and (ii) increased compliance costs for us and our tenants, in each case] without a corresponding increase in revenue.

Rewritten

Life [removed: science industry] [added: science industry] changes could have a material adverse effect on our business, results of [removed: operations] [added: operations,] and financial condition.

Rewritten

If economic, financial, regulatory, or industry conditions [added: continue to] adversely affect the life science industry, we may be unable to lease or re-lease our [removed: life science] [added: lab] properties in a timely manner or at [removed: favorable] [added: profitable] rates or with favorable terms.

Rewritten

In addition, because [removed: life science] [added: lab] property infrastructure improvements are typically significantly more costly than improvements to other property types due to their highly specialized nature, and [removed: life science] [added: lab] tenants typically require greater lease square footage relative to [added: outpatient] medical [removed: office] tenants, repositioning efforts would have a disproportionate adverse effect on our [removed: life science] [added: lab] segment performance.

Rewritten

Further, [added: our lab investments could face decreased demand from biotech and] life science [added: companies relative to supply, and life science] industry consolidation could reduce the rentable square footage requirements of our client tenants and prospective client tenants, which may adversely impact our revenues from lease payments.

Rewritten

Finally, our [removed: life science] [added: lab] investments could also be adversely affected if the life science industry migrates from the U.S. to other countries or to areas outside of our primary [removed: life science] [added: lab] markets in the greater [added: South] San Francisco, San Diego, and Boston areas.

Rewritten

Our [removed: life science] [added: lab] tenants face significant regulation, funding requirements, and uncertainty.

Rewritten

Our [removed: life science] [added: lab] tenants face substantial requirements for, and risks related to, the research, development, clinical testing, manufacture, and commercialization of their products and technologies, including:

Rewritten

Our [removed: life science] [added: lab] tenants’ ability to raise capital depends on the actual or perceived viability of their products and technologies, their financial and operating condition and outlook, and the overall financial, banking, and economic environment.

Rewritten

If our [removed: life science] [added: lab] tenants’ businesses are adversely affected, they may fail to make their rent payments to us, which could have a material adverse effect on our business, results of operations, and financial condition.

Rewritten

The hospitals on whose campuses our [removed: MOBs] [added: outpatient medical buildings] are located and their affiliated healthcare systems could fail to remain competitive or financially viable, which could adversely impact their ability to attract physicians and physician groups to our [removed: MOBs] [added: outpatient medical buildings] and our other properties that serve the healthcare industry.

Rewritten

If a hospital whose campus is located near one of our [removed: MOBs] [added: outpatient medical buildings] is unable to meet its financial obligations, and if an affiliated healthcare system is unable to support that hospital or goes bankrupt, the hospital may be unable to successfully compete or could be forced to close or relocate, which could adversely impact its ability to attract physicians and other healthcare-related users.

New in FY2023

Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business.

New in FY2023

- risks relating to the Mergers;

New in FY2023

- risks relating to the Combined Company following the Mergers;

New in FY2023

- risks relating to the status of Physicians Realty Trust as a REIT; and

New in FY2023

- risks relating to an investment in the Combined Company’s common stock following the Mergers and the transactions contemplated by the Merger Agreement.

New in FY2023

These macroeconomic trends have been, and may continue to be, exacerbated by responses to the Covid pandemic, supply chain disruptions, the conflicts between Russia and Ukraine and in the Middle East, federal government deficits, and other international and domestic events impacting the macroeconomic environment.

New in FY2023

U.S. government policies implemented to address inflation, including actions by the Federal Reserve System’s Federal Open Market Committee (the “FOMC”) to increase short-term interest rates, have led to increases in interest rates in the credit markets and other impacts on the macroeconomic environment.

New in FY2023

The FOMC may continue to raise the federal funds rate or maintain a higher federal funds rate for a longer period of time, either of which would likely lead to higher short-term interest rates and the possibility of lower asset values, slowing economic growth and increasing the possibility of a recession.

New in FY2023

Further, actions by the FMOC to decrease short-term interest rates could lead to inflationary pressures.

New in FY2023

Increased interest rates could also negatively impact consumer spending and our tenants’, operators’, and borrowers’ businesses and future demand for our properties.

New in FY2023

Additionally, changing technologies and cultural trends could negatively impact future demand for our properties, which could have a material adverse effect on our business, results of operations, and financial condition.

New in FY2023

- economic conditions restricting growth opportunities.

New in FY2023

Our tenants, operators, and borrowers could also be adversely impacted by a bank failure or other event affecting financial institutions, including through disruptions in access to bank deposits or borrowing capacity, including access to letters of credit from certain of our tenants relating to lease obligations, and any resulting adverse effects to our tenants’, operators’, or borrowers’ liquidity or financial performance could affect their ability to meet their financial and other contractual obligations to us.

New in FY2023

We have been subject to rejection of our leases in the past and may experience such rejection in the future.

New in FY2023

Moreover, an increase in volatility and difficulty predicting adverse weather events, such as freeze events in warmer climates in recent years, as well as increased hurricane intensity, may result in additional losses.

New in FY2023

Intensifying natural disasters including climate change and extreme weather events, coupled with the current economic climate have directly affected the availability of insurance, premiums, deductibles, and capacity that insurers are willing to underwrite.

New in FY2023

As a result, we may determine to self-insure more of our exposures, absorb more below deductible losses, and look for alternative means of risk transfer in order to avoid spiraling insurance costs.

New in FY2023

These events also have indirect effects on our business by increasing the costs of energy, maintenance, and snow removal at our properties.

New in FY2023

In addition, the rise in outsized jury verdicts and/or intensifying natural disasters could threaten policy limits and/or sublimits, which may result in the exhaustion of available insurance coverage for the remainder of the policy year.

New in FY2023

These events could also have a material adverse effect on our business, results of operations, and financial condition.

New in FY2023

- our joint venture agreements may give our partners management rights that allow them to make operational or other decisions with which we disagree or that we would manage differently; and

New in FY2023

- our joint venture agreements may impose limitations or caps on the property management fees that we otherwise would have been entitled to receive if the underlying property were wholly owned.

New in FY2023

Alternatively, we may determine to sell a distressed loan for less than full value, in which event we may incur a loss on the investment.

New in FY2023

We may be required to recognize reserves, allowances, credit losses, or impairment charges.

New in FY2023

Declines in the value of our properties or other assets or loan collateral, financial deterioration of our tenants, borrowers, or other obligors, or other factors may result in the recognition of reserves, allowances, credit losses, or impairment charges.

New in FY2023

Our determination of such reserves, allowances, or credit losses relies on estimates regarding the fair value of any loan collateral, which is a complex and subjective process.

New in FY2023

In addition, we evaluate our assets for impairments based on various triggers, including market conditions, our current intentions with respect to holding or disposing of the assets and the expected future undiscounted cash flows from the assets.

New in FY2023

Impairments, reserves, allowances, and credit losses are based on estimates and assumptions that are inherently uncertain, may increase or decrease in the future, and may not represent or reflect the ultimate value of, or loss that we ultimately realize with respect to, the relevant assets.

New in FY2023

Any such impairment, reserve, allowance, or credit loss, or any change in any of the foregoing, could have an adverse impact on our results of operations and financial condition.

New in FY2023

For additional information on risks related to the consummation of the Mergers, see “—Risks Relating to the Mergers” below.

New in FY2023

ESG and sustainability commitments and requirements, as well as stakeholder expectations, may impose additional costs and expose us to new risks.

New in FY2023

Investors, tenants, business partners and other stakeholders, as well as regulators and other groups, are increasingly focusing on ESG and sustainability commitments and performance.

New in FY2023

Some investors may use ESG factors to guide their investment strategies and, in some cases, may choose not to invest in us if our ESG commitment and performance do not satisfy their criteria.

New in FY2023

Similarly, some business partners or tenants may use ESG factors to guide their business decisions and choose not to do business with us if they believe our ESG or sustainability policies are inadequate.

New in FY2023

Third-party providers of ESG ratings have increased in number, resulting in varied and, in some cases, inconsistent standards.

New in FY2023

In addition, the criteria by which companies’ ESG and sustainability practices are assessed are evolving, which could result in greater expectations for us to undertake costly initiatives to satisfy such new criteria.

New in FY2023

We have established corporate goals to reduce greenhouse gas emissions, energy, water and waste in our operations, and various regions in which we own properties are establishing building performance standards.

New in FY2023

Our reputation may be adversely affected if we do not meet our announced goals or these external standards.

New in FY2023

If we fail to satisfy the expectations of investors, tenants, business partners or other stakeholders, or our announced goals and other initiatives are not executed as planned, our reputation and financial results could be adversely affected, and our revenues, results of operations and ability to grow our business may be negatively impacted.

New in FY2023

In addition, we may incur significant costs in attempting to comply with ESG policies or third party expectations or demands.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

- economic feasibility risks.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

Generally, insurance coverage for pandemics has not been readily available and, if and when it does become available, may not be on commercially reasonable terms.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

Recent increases in interest rates have increased interest costs for our variable rate debt and our new debt, and interest rates may continue to rise.

Dropped from FY2022

These interest rates make the financing of any acquisition and development activity more costly.

Dropped from FY2022

If our prevailing borrowing costs are higher than the interest rates of our senior notes at their maturity, we will incur additional interest expense upon any replacement debt.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

- statutory and regulatory changes;

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

Sometimes, governmental payors freeze or reduce payments to healthcare providers, or provide annual reimbursement rate increases that are smaller than expected, due to budgetary and other pressures.

Dropped from FY2022

Furthermore, executive orders and legislation may amend the Patient Protection and Affordable Care Act, along with the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”) and related regulations in whole or in part.

Dropped from FY2022

We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare system.

Dropped from FY2022

For example, the Department of Health and Human Services has focused on tying Medicare payments to quality or value through alternative payment models, which generally aim to make providers attentive to the total costs of treatments.

Dropped from FY2022

Medicare no longer reimburses hospitals for care related to certain preventable adverse events and imposes payment reductions on hospitals for preventable readmissions.

Dropped from FY2022

These punitive approaches could be expanded to additional types of providers in the future.

Dropped from FY2022

If any such changes significantly and adversely affect our tenants’ or borrowers’ profitability, they could in turn negatively affect our tenants’ or borrowers’ ability and willingness to comply with the terms of their leases and/or loan documents with us and/or renew their leases with us upon expiration or repay their loans upon maturity, which could impact our business, prospects, financial condition, or results of operations.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

HHS has stated that compliance with PRF program terms and conditions is material to HHS’s decision to disburse PRF payments to recipients.

Dropped from FY2022

HHS interpretation of these terms and requirements regarding eligibility, use of funds, audit, and reporting continues to evolve and there is a high degree of uncertainty surrounding interpretation and implementation, particularly among more complex corporate, transactional, and contractual relationships, including RIDEA structures and for organizations with multiple recipient subsidiaries.

Dropped from FY2022

Changing PRF program requirements could reduce the amount of PRF funds we receive or are permitted to retain and could render us or our operators ineligible for future or previously received PRF funds.

Dropped from FY2022

PRF reporting obligations and monitoring and compliance efforts could impose substantial costs, become overly burdensome, and require significant attention from leadership, disrupting our business and impeding our operations.

Dropped from FY2022

Further, our current and former operators may not consistently use, account for, or document PRF and other relief funds, which may adversely impact availability of data and consistency in our reporting, including among current and former operators and across reporting periods.

Dropped from FY2022

Ultimately, as PRF program requirements and interpretations continue to evolve, we may determine that we are unable to comply with certain terms and conditions, or that we are no longer eligible for some or all of the PRF payments we or our operators previously received.

Dropped from FY2022

If we are unable to fully comply with applicable PRF terms and conditions, we may be required to return some or all PRF funds received and may be subject to further enforcement action.

Dropped from FY2022

Due to our and our operators’ participation in the PRF program, we may be subject to government and other audits and investigations related to our receipt and use of PRF funds.

Dropped from FY2022

These audits and investigations also may impose substantial costs and disruptions.

Dropped from FY2022

If the government determines that we failed to comply with PRF terms and conditions, related interpretative guidance, or applicable federal award requirements, or that our PRF applications and submissions were defective, PRF funds that we or our operators have received may be subject to recoupment and further enforcement actions could result.

Dropped from FY2022

This could occur even if our interpretation of PRF program requirements was reasonable under the present or then-existing PRF guidance and HHS interpretations.

Dropped from FY2022

Government audits and investigations also could result in other regulatory penalties or enforcement actions, including actions under the False Claims Act (“FCA”), which prohibits false claims for payments to, or improper retention of overpayments from, the government.

An excerpt. Shown here: 40 of 118 rewritten, 40 of 237 added and 40 of 43 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2023 filing and the FY2022 filing.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

245 rewritten, 119 added, 143 removed, 210 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

This section generally discusses the results of our operations for the year ended December 31, [removed: 2022] [added: 2023] compared to the year ended December 31, [removed: 2021.][added: 2022.]

Rewritten

For a discussion of the year ended December 31, [removed: 2021] [added: 2022] compared to the year ended December 31, [removed: 2020,] [added: 2021,] please refer to Part II, Item 7.

Rewritten

“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, [removed: 2021] [added: 2022] filed with the SEC on February [removed: 9, 2022.][added: 8, 2023.]

Rewritten

[removed: - Overview of Transactions][added: Overview]

Rewritten

Our operating results have been and will continue to be impacted by global and national economic and market conditions generally and by the local economic conditions where our properties are [removed: located, as well as by the Covid pandemic.][added: located.]

Rewritten

Rising interest rates, high inflation, supply chain disruptions, ongoing geopolitical tensions, and increased volatility in public [added: and private] equity and fixed income markets have led to increased costs and limited the availability of capital.

Rewritten

[removed: To the extent our] [added: Our] tenants [removed: or] [added: and] operators [removed: experience] [added: have also experienced] increased [removed: costs or] [added: costs, liquidity constraints, and] financing difficulties due to the foregoing macroeconomic [added: and market] conditions, [removed: they may] [added: which could cause them to] be unable or unwilling to make payments or perform their obligations when due.

Rewritten

In addition, increased interest rates [removed: could affect] [added: have negatively affected] our borrowing [removed: costs and] [added: costs,] the fair value of our fixed rate instruments.

Rewritten

We have also been affected by significant inflation in construction costs over the past [removed: couple of] [added: few] years, which, together with rising costs of capital, have negatively affected the expected yields on our development and redevelopment projects.

Rewritten

We continuously monitor the effects of domestic and global events, including but not limited to inflation, labor shortages, supply chain matters, rising interest rates, and [removed: other current and expected impacts of] [added: challenges in] the [removed: Covid pandemic] [added: financial markets,] on our operations and financial position, as well as on the operations and financial position of our tenants, operators, and borrowers, to ensure that we remain responsive and adaptable to the dynamic changes in our operating environment.

Rewritten

See “Item 1A, Risk Factors” in this report for additional discussion of the risks posed by macroeconomic [removed: conditions and the Covid pandemic,] [added: conditions,] as well as the uncertainties we and our tenants, operators, and borrowers may face as a result.

Rewritten

[removed: In] [added: *•*In] January 2023, we [removed: closed] [added: acquired] a [removed: life science acquisition] [added: lab land parcel] in Cambridge, Massachusetts for $9 million.

Rewritten

[removed: Other Real] [added: Real] Estate Transactions

Rewritten

- In January 2023, we sold two [removed: life science facilities] [added: lab buildings] in Durham, North Carolina for $113 million.

Rewritten

[removed: -] In [removed: August 2022,] [added: January 2024,] we entered into [removed: two] forward-starting interest rate swap instruments that are designated as cash flow hedges that [added: will] effectively establish a fixed interest rate for the [removed: 2022] [added: 2024] Term Loan [removed: Facilities.][added: at a blended contractual rate of 4.5%.]

Rewritten

- In January 2023, we completed a public offering of $400 million aggregate principal amount of 5.25% senior unsecured notes due [removed: in] 2032.

Rewritten

Quarterly cash dividends paid during [removed: 2022] [added: 2023] aggregated to $1.20 per share.

Rewritten

On [removed: February 1, 2023,] [added: January 31, 2024,] our Board of Directors declared a quarterly cash dividend of $0.30 per common share.

Rewritten

The dividend will be paid on February [removed: 23, 2023] [added: 26, 2024] to stockholders of record as of the close of business on February [removed: 9, 2023.][added: 14, 2024.]

Rewritten

We evaluate our business and allocate resources among our reportable business segments: (i) [removed: life science,] [added: lab,] (ii) [removed: medical office,] [added: outpatient medical,] and (iii) CCRC.

Rewritten

We have other non-reportable segments that are comprised primarily of: (i) an interest in our unconsolidated SWF SH [removed: JV,] [added: JV and] (ii) loans [removed: receivable, and (iii) marketable debt securities.][added: receivable.]

Rewritten

NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss) as presented in Note [removed: 16] [added: 15] to the Consolidated Financial Statements.

Rewritten

For a reconciliation of NOI and Adjusted NOI to net income (loss) by segment, refer to Note [removed: 16] [added: 15] to the Consolidated Financial Statements.

Rewritten

Operating expenses generally relate to leased [added: outpatient] medical [removed: office] and [removed: life science properties,] [added: lab buildings,] as well as CCRC facilities.

Rewritten

We generally recover all or a portion of our leased [added: outpatient] medical [removed: office] and [removed: life science] [added: lab] property expenses through tenant recoveries.

Rewritten

Same-Store Adjusted NOI [added: also] excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.

Rewritten

In addition, we present Nareit FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, [removed: transaction-related] [added: transaction and merger-related] items, other impairments (recoveries) and other losses (gains), restructuring and severance-related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), [removed: foreign currency remeasurement losses (gains),] deferred tax asset valuation allowances, and changes in tax legislation (“FFO as Adjusted”).

Rewritten

[removed: Transaction-related] [added: Transaction and merger-related] items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities.

Rewritten

*Adjusted FFO (“AFFO”).* AFFO is defined as FFO as Adjusted after excluding the impact of the following: (i) [removed: amortization of] stock-based [removed: compensation,] [added: compensation amortization expense,] (ii) amortization of deferred financing costs, net, (iii) straight-line rents, (iv) deferred income taxes, [removed: and] (v) [removed: other AFFO adjustments, which include: (a)] amortization of [removed: acquired] [added: above (below)] market lease intangibles, net, [removed: (b)] [added: and (vi) other AFFO adjustments, which include: (a)] non-cash interest related to DFLs and lease incentive amortization (reduction of straight-line rents), [removed: (c)] [added: (b)] actuarial reserves for insurance claims that have been incurred but not reported, and [removed: (d)] [added: (c)] amortization of deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents.

Rewritten

AFFO is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP and should only be considered together with and as a supplement to [removed: the Company’s] [added: our] financial information prepared in accordance with GAAP.

Rewritten

For a reconciliation of net income (loss) to AFFO and other relevant [removed: disclosure,] [added: disclosures,] refer to “Non-GAAP Financial Measures Reconciliations” below.

Rewritten

Comparison of the Year Ended December 31, [removed: 2022] [added: 2023] to the Year Ended December 31, [removed: 2021][added: 2022]

Rewritten

[removed: *2022] [added: *2023] and [removed: 2021*][added: 2022(1)*]

Rewritten

The following table summarizes results for the years ended December 31, [removed: 2022] [added: 2023] and [removed: 2021] [added: 2022] (in thousands):

Rewritten

| | | | | | | [removed: 2022] [added: 2023] | | | | | | [removed: 2021] [added: 2022] | | | | | | | | | | | | | | | | | | Change | | |

Rewritten

| Net income (loss) applicable to common shares | | | [removed: | | |] $ | [removed: 497,792] [added: 304,284] | | | | | $ | [removed: 502,271 | | | | | | | | | | | |] [added: 497,792] | | | | | $ | [removed: (4,479)] [added: 502,271] | |

Rewritten

| Nareit FFO [removed: | | | | | | 895,166 | | | | | | 604,726 | | |] [added: applicable to common shares] | | | [added: 985,180] | | | | | | [added: 895,166] | | | | | | [removed: 290,440] [added: 604,726] | | |

Rewritten

| FFO as Adjusted [removed: | | | | | | 940,933 | | | | | | 870,645 | | |] [added: applicable to common shares] | | | [added: $] | [added: 978,306] | | | | | [added: $] | [added: 940,933] | | | | | [removed: 70,288] [added: $] | [added: 870,645] | |

Rewritten

| AFFO [removed: | | | | | | 783,702 | | | | | | 727,870 | | |] [added: applicable to common shares] | | | [added: 840,777] | | | | | | [added: 783,702] | | | | | | [removed: 55,832] [added: 727,870] | | |

Rewritten

[removed: *•*an increase] [added: - a decrease] in general and administrative expenses, primarily as a result of: (i) severance-related charges associated with the departures of our former Chief Executive Officer and our former Chief Legal Officer and General Counsel in the fourth quarter of 2022 and (ii) charges incurred in connection with the downsizing of our corporate headquarters in Denver, [removed: Colorado;][added: Colorado in the fourth quarter of 2022;]

New in FY2023

- Company Highlights

New in FY2023

and real estate values generally, including our real estate.

New in FY2023

Company Highlights

New in FY2023

As of February 10, 2023, we are structured as an UPREIT.

New in FY2023

This structure provides prospective sellers an alternative for disposing of property that has appreciated in value in a tax-deferred manner to Healthpeak OP and aligns our corporate structure with other publicly traded U.S. real estate investment trusts.

New in FY2023

Following the Reorganization, Healthpeak OP is the borrower under, and we are the guarantor of, all of the unsecured debt, which includes the Revolving Facility, Term Loan Facilities (each as defined below), commercial paper program, and senior unsecured notes.

New in FY2023

Our guarantee of the senior unsecured notes is full and unconditional and applicable to existing and future senior unsecured notes.

New in FY2023

The Reorganization did not have a material impact on our financial position, consolidated financial statements, outstanding debt securities, material debt facilities, or business operations.

New in FY2023

On October 29, 2023, we entered into a Merger Agreement with Physicians Realty Trust, the Physicians Partnership, and certain of our subsidiaries, pursuant to which, among other things, and through a series of transactions (the “Mergers”), (i) each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares to be canceled in accordance with the Merger Agreement) will be converted into the right to receive 0.674 (the “Exchange Ratio”) shares of our common stock, and (ii) each outstanding common unit of the Physicians Partnership will be converted into common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.

New in FY2023

In connection with the Mergers, we filed a Registration Statement on Form S-4 with the SEC on December 15, 2023, as amended on January 9, 2024, and a definitive joint proxy statement/prospectus for the Company and Physicians Realty Trust on January 11, 2024 in connection with our respective special meetings of stockholders and shareholders, as applicable, which will be held on February 21, 2024.

New in FY2023

We expect the Mergers to close on March 1, 2024.

New in FY2023

Following the transactions contemplated in the Merger Agreement, the successor entities to Physicians Realty Trust and the Physicians Partnership will be direct and indirect subsidiaries of Healthpeak OP, respectively.

New in FY2023

Consummation of the Mergers are subject to the satisfaction or waiver of customary closing conditions, including the approval of our stockholders and the shareholders of Physicians Realty Trust.

New in FY2023

- In March 2023, we sold two outpatient medical buildings for $32 million.

New in FY2023

- In April 2023, we acquired the remaining 80% interest in one of the outpatient medical buildings in the Ventures IV unconsolidated joint venture for $4 million.

New in FY2023

- In January 2024, we sold a 65% interest in two lab buildings in San Diego, California to a third-party for net proceeds of $128 million.

New in FY2023

- During the year ended December 31, 2023, the following projects were placed in service: (i) portions of two lab development projects with aggregate costs of $233 million, (ii) one lab development project with total costs of $171 million, (iii) a portion of one lab redevelopment project with total costs of $43 million, (iv) four outpatient medical redevelopment projects with aggregate costs of $42 million, (v) a portion of one lab redevelopment building held in one of our unconsolidated South San Francisco JVs of which our share of total project costs was $32 million, (vi) one lab redevelopment building held in one of our unconsolidated South San Francisco JVs of which our share of total project costs was $15 million, (vii) one lab redevelopment project with total costs of $14 million, and (viii) one CCRC redevelopment project with total costs of $7 million.

New in FY2023

- In May 2023, we completed a public offering of $350 million aggregate principal amount of 5.25% senior unsecured notes due 2032, which constituted an additional issuance of, and are treated as a single series with, the $400 million of senior unsecured notes due 2032 issued in January 2023.

New in FY2023

- In December 2023, a mortgage loan secured by one CCRC with a principal balance of $85 million matured and was repaid.

New in FY2023

- We have secured commitments for a $750 million five-year unsecured term loan (the “2024 Term Loan”), to be incurred as an incremental facility under our existing term loan agreement.

New in FY2023

Other Activities

New in FY2023

*•*In February 2023, we received a partial principal repayment of $102 million on one secured loan.

New in FY2023

*•*In February 2023, we received full repayment of the outstanding balance of one $35 million secured loan.

New in FY2023

- In April 2023, we received full repayment of the outstanding balance of one $14 million secured loan.

New in FY2023

- In May 2023, we received full repayment of two outstanding secured loans with an aggregate balance of $12 million.

New in FY2023

- In October 2023, we received full repayment of the outstanding balance of one $21 million secured loan.

New in FY2023

Under the lab and outpatient medical segments, we invest through the acquisition, development, and management of lab buildings, outpatient medical buildings, and hospitals.

New in FY2023

These non-reportable segments have been presented on an aggregate basis herein.

New in FY2023

Same-Store NOI and Adjusted NOI exclude government grant income under the CARES Act.

New in FY2023

| Nareit FFO | | | | | | 985,180 | | | | | | 895,166 | | | | | | | | | | | | | | | | | | 90,014 | | |

New in FY2023

| FFO as Adjusted | | | | | | 978,306 | | | | | | 940,933 | | | | | | | | | | | | | | | | | | 37,373 | | |

New in FY2023

| AFFO | | | | | | 840,777 | | | | | | 783,702 | | | | | | | | | | | | | | | | | | 57,075 | | |

New in FY2023

*•*an increase in transaction and merger-related costs, primarily as a result of costs related to the Mergers, which are primarily comprised of legal, accounting, tax, and other costs that were incurred during the fourth quarter of 2023; and

New in FY2023

*•*an increase in gains on sale of depreciable real estate related to lab and outpatient medical building sales during 2023 as compared to 2022;

New in FY2023

- a decrease in depreciation related to the deconsolidation of seven previously consolidated lab buildings in South San Francisco, California during the third quarter of 2022;

New in FY2023

*•*an increase in income tax benefit primarily as a result of a $14 million tax benefit recognized in connection with the reversal of a deferred tax asset valuation allowance during the fourth quarter of 2023;

New in FY2023

- a decrease in loan loss reserves primarily as a result of principal repayments on seller financing;

New in FY2023

- an increase in equity income from unconsolidated joint ventures; and

New in FY2023

- a decrease in casualty-related charges from a hurricane during the third quarter of 2022.

New in FY2023

Included in our total property portfolio at each of December 31, 2023 and 2022 are 19 senior housing assets in our SWF SH JV.

Dropped from FY2022

In addition, labor shortages and global supply chain disruptions, including procurement delays and long lead times on certain materials, have adversely impacted and could continue to adversely impact the scheduled completion and/or costs of these projects.

Dropped from FY2022

Further, the full, long-term economic impact of the Covid pandemic on the operations of our CCRCs and the senior housing facilities owned by our SWF SH JV remains uncertain.

Dropped from FY2022

Many factors cannot be predicted and will remain unpredictable, including the impact, duration, and severity of new variants and outbreaks.

Dropped from FY2022

Due to these uncertainties, at this time, we are not able to estimate the full impact of Covid on our consolidated financial position, results of operations, and cash flows in the future.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

Overview of Transactions

Dropped from FY2022

South San Francisco Joint Ventures

Dropped from FY2022

On August 1, 2022, we sold a 30% interest in seven life science assets in South San Francisco, California to a sovereign wealth fund for cash of $126 million.

Dropped from FY2022

67 Smith Place

Dropped from FY2022

In January 2022, we closed a life science acquisition in Cambridge, Massachusetts for $72 million.

Dropped from FY2022

Vista Sorrento Phase II

Dropped from FY2022

In January 2022, we closed a life science acquisition in San Diego, California for $24 million.

Dropped from FY2022

Webster MOB Portfolio

Dropped from FY2022

In March 2022, we acquired a portfolio of two MOBs in Houston, Texas for $43 million.

Dropped from FY2022

Northwest Medical Plaza

Dropped from FY2022

In May 2022, we acquired one MOB in Bentonville, Arkansas for $26 million.

Dropped from FY2022

Concord Avenue Land Parcels

Dropped from FY2022

In December 2022, we closed a life science acquisition in Cambridge, Massachusetts for $18 million.

Dropped from FY2022

Land Parcel Acquisition Subsequent to Year-End

Dropped from FY2022

- During the year ended December 31, 2022, we sold one life science facility in Utah for $14 million.

Dropped from FY2022

- During the year ended December 31, 2022, we sold our remaining hospital under a direct financing lease (“DFL”) for $68 million.

Dropped from FY2022

- During the year ended December 31, 2022, we sold five MOBs and one MOB land parcel for $36 million.

Dropped from FY2022

- In April 2022, we terminated our existing interest rate cap instruments associated with $142 million of variable rate mortgage debt and entered into two interest rate swap instruments that are designated as cash flow hedges and mature in May 2026.

Dropped from FY2022

- In July 2022, we increased the maximum aggregate face or principal amount that can be outstanding at any one time under the commercial paper program from $1.5 billion to $2.0 billion.

Dropped from FY2022

- In August 2022, we executed a term loan agreement that provides for two senior unsecured delayed draw term loans in an aggregate principal amount of up to $500 million (the “2022 Term Loan Facilities”).

Dropped from FY2022

In October 2022, the entirety of the $500 million under the 2022 Term Loan Facilities was drawn.

Dropped from FY2022

- In August 2022, our Board of Directors approved the Share Repurchase Program under which we may acquire shares of our common stock in the open market up to an aggregate purchase price of $500 million.

Dropped from FY2022

During the year ended December 31, 2022, we repurchased 2.1 million shares of our common stock under our Share Repurchase Program at a weighted average price of $27.16 per share for a total of $56 million.

Dropped from FY2022

- In December 2022, we settled all 9.1 million shares previously outstanding under forward contracts under our ATM Program (as defined below) at a weighted average net price of $34.01 per share, after commissions, resulting in net proceeds of $308 million.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

- During the year ended December 31, 2022, the following projects were placed in service: (i) three MOB development projects with total costs of $58 million, (ii) three MOB redevelopment projects with total costs of $32 million, (iii) four life science development projects with total costs of $317 million, (iv) two life science redevelopment projects with total costs of $104 million, and (v) a portion of two life science development projects with total costs of $193 million.

Dropped from FY2022

Under the life science and medical office segments, we invest through the acquisition, development, and management of life science facilities, MOBs, and hospitals, which generally requires a greater level of property management.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

Overview(1)

Dropped from FY2022

*•*a decrease in income from discontinued operations, primarily as a result of a decrease in gain on sales of real estate from dispositions of our senior housing portfolios, partially offset by lower impairments of depreciable real estate and goodwill;

Dropped from FY2022

- a decrease in gains on sale of depreciable real estate, primarily related to the Hoag Hospital sale in May 2021;

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

*•*an increase in loan loss reserves in 2022 primarily due to macroeconomic conditions and increased interest rates; and

An excerpt. Shown here: 40 of 245 rewritten, 40 of 119 added and 40 of 143 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the FY2023 filing and the FY2022 filing.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

11 rewritten, 0 added, 9 removed, 11 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

We are exposed to various market risks, [removed: including] [added: primarily from] the potential loss arising from adverse changes in interest rates.

Rewritten

Derivatives are recorded on the Consolidated Balance Sheets at fair value (see Note [removed: 22] [added: 21] to the Consolidated Financial Statements).

Rewritten

At December 31, [removed: 2022,] [added: 2023,] a one percentage point increase or decrease in the underlying interest rate curve would result in a corresponding increase or decrease in the fair value of the derivative instruments by [removed: approximately $23] [added: up to $18] million.

Rewritten

At December 31, [removed: 2022,] [added: 2023,] our exposure to interest rate risk was primarily on our variable rate debt.

Rewritten

At December 31, [removed: 2022,] [added: 2023,] $142 million of our variable rate mortgage debt [removed: was] [added: and our $500 million Term Loan Facilities were] swapped to fixed [added: rates] through interest rate swap instruments.

Rewritten

At December 31, [removed: 2022,] [added: 2023,] both the fair value and carrying value of the interest rate swap instruments were [removed: $30] [added: $21] million.

Rewritten

Our remaining variable rate debt at December 31, [removed: 2022] [added: 2023] was comprised of [added: borrowings under] our commercial paper program and certain of our mortgage debt.

Rewritten

At December 31, [removed: 2022,] [added: 2023,] a one percentage point increase in interest rates would decrease the fair value of our fixed rate debt by approximately [removed: $214] [added: $255] million and a one percentage point decrease in interest rates would increase the fair value of our fixed rate debt by approximately [removed: $229] [added: $272] million.

Rewritten

[removed: Additionally,] [added: Assuming] a one percentage point increase [removed: or decrease] in [added: the] interest rates [removed: would change the fair value of] [added: related to] our [removed: fixed] [added: variable] rate [removed: debt investments] [added: debt, and assuming no other changes in the outstanding balance at December 31, 2023, our annual interest expense would increase] by approximately [removed: $1] [added: $7] million.

Rewritten

Conversely, changes in interest rates on variable rate debt [removed: and investments] would change our future earnings and cash flows, but not materially impact the fair value of those instruments.

Rewritten

[removed: Assuming] [added: Lastly, assuming] a one percentage point [removed: increase] [added: decrease] in the interest rates related to our variable rate [removed: debt,] [added: loans receivable,] and assuming no other changes in the outstanding balance at December 31, [removed: 2022,] [added: 2023,] our annual interest [removed: expense] [added: income] would [removed: increase] [added: decrease] by approximately [removed: $10] [added: $2] million.

Dropped from FY2022

At December 31, 2022, the $500 million 2022 Term Loan Facilities were swapped to fixed through forward-starting interest rate swap instruments.

Dropped from FY2022

Lastly, assuming a one percentage point decrease in the interest rates related to our variable rate loans receivable, and assuming no other changes in the outstanding balance at December 31, 2022, our annual interest income would decrease by $2 million.

Dropped from FY2022

Market Risk

Dropped from FY2022

We have investments in marketable debt securities classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity.

Dropped from FY2022

Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization of premiums and discounts through maturity.

Dropped from FY2022

We consider a variety of factors in evaluating an other-than-temporary decline in value, such as: the length of time and the extent to which the market value has been less than our current adjusted carrying value; the issuer’s financial condition, capital strength, and near-term prospects; any recent events specific to that issuer and economic conditions of its industry; and our investment horizon in relationship to an anticipated near-term recovery in the market value, if any.

Dropped from FY2022

At December 31, 2022, both the fair value and carrying value of marketable debt securities was $22 million.

Dropped from FY2022

These securities matured on December 31, 2022, and we received the related proceeds in January 2023.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Item 1. Business

61 rewritten, 31 added, 36 removed, 187 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

[removed: As of December 31,] [added: In] 2020, we concluded that the [removed: planned] dispositions [added: of our senior housing triple-net and senior housing operating property (“SHOP”) portfolios] represented a strategic shift that had [removed: and will have] a major effect on our operations and financial results.

Rewritten

Therefore, the [added: results of senior housing triple-net and SHOP] assets are classified as discontinued operations in all periods presented herein.

Rewritten

See Note [removed: 5] [added: 4] to the Consolidated Financial Statements for further information regarding discontinued operations.

Rewritten

[removed: In conjunction with the disposal of our senior housing triple-net and SHOP portfolios, we focused our strategy on investing in] [added: We have] a diversified portfolio of high-quality healthcare properties across [removed: our] three core asset classes of [removed: life science, medical office,] [added: lab, outpatient medical,] and continuing care retirement community (“CCRC”) real estate.

Rewritten

Under the [removed: life science] [added: lab] and [added: outpatient] medical [removed: office] segments, we invest through the acquisition, development, and management of [removed: life science facilities, MOBs,] [added: lab buildings, outpatient medical buildings,] and hospitals.

Rewritten

We have other non-reportable segments that are comprised primarily of loans [removed: receivable, marketable debt securities,] [added: receivable] and an interest in an unconsolidated joint venture that owns 19 senior housing assets (our “SWF SH JV”).

Rewritten

At December 31, [removed: 2022,] [added: 2023,] our portfolio of investments, including properties in our unconsolidated joint ventures, consisted of interests in [removed: 480] [added: 477] properties.

Rewritten

The following table summarizes information for our reportable [removed: segments, excluding discontinued operations,] [added: and other non-reportable segments] for the year ended December 31, [removed: 2022] [added: 2023] (dollars in thousands):

Rewritten

| Other non-reportable | | | | | | [removed: 16,920] [added: 22,210] | | | | | | [removed: 2] [added: 1.8] | | % | | | | 19 | | |

Rewritten

See “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures” for additional information regarding Adjusted NOI and see Note [removed: 16] [added: 15] to the Consolidated Financial Statements for a reconciliation of Adjusted NOI by segment to net income (loss).

Rewritten

For a description of our significant activities during [removed: 2022,] [added: 2023,] see “Item 7, Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations—Overview of Transactions”] [added: Operations—Company Highlights”] in this report.

Rewritten

We [removed: invest in and] manage our real estate portfolio for the long-term to maximize [removed: benefit to our stockholders] [added: risk-adjusted returns] and support the growth of our dividends.

Rewritten

(i)Our *real estate*: Our portfolio [removed: is grounded in] [added: consists of] high-quality properties in desirable locations.

Rewritten

(iii)Our *partnerships*: We work with leading [removed: pharmaceutical] [added: pharmaceutical, biotechnology,] and [removed: biotechnical] [added: medical device] companies, [added: as well as] healthcare [removed: companies, operators,] [added: delivery systems, specialty physician groups,] and [added: other healthcare] service [removed: providers and are responsive] [added: providers,] to [added: meet] their [removed: space and capital] [added: real estate] needs.

Rewritten

We continually strive to create and maintain an industry-leading [removed: platform] [added: platform,] with systems and tools that allow us to effectively and efficiently manage our assets and investment activity.

Rewritten

Our strategy for maximizing the benefits from these opportunities is to: (i) work with new or existing tenants [removed: and operators] to address their space and capital needs and (ii) provide high-quality property management services in order to motivate tenants to renew, expand, or relocate into our properties.

Rewritten

- Build and maintain long-term leasing and management relationships with quality [removed: tenants and operators.][added: tenants.]

Rewritten

In choosing locations for our properties, we focus on the physical environment, adjacency to established businesses (e.g., hospital [removed: systems)] [added: systems or life science submarkets)] and educational centers, proximity to sources of business growth, and other local demographic factors.

Rewritten

We [added: selectively] structure lease extensions, early renewals, or modifications, which reduce the cost associated with lease downtime, while securing the tenancy and relationship of our [removed: high quality] [added: high-quality] tenants on a long-term basis.

Rewritten

The [added: discovery and] delivery of healthcare services requires real estate and, as a result, tenants [removed: and operators] depend on [added: our] real estate, in part, to maintain and grow their businesses.

Rewritten

We may take additional measures to mitigate risk, including diversifying our investments (by sector, geography, [removed: tenant, or operator),] [added: and tenant),] structuring transactions as master leases, requiring tenant or operator insurance and indemnifications, and/or obtaining credit enhancements in the form of guarantees, letters of credit, or security deposits.

Rewritten

- our reputation gained through [removed: over three] decades of successful operations and the strength of our existing portfolio of properties;

Rewritten

We may finance acquisitions and other investments [removed: primarily through the following vehicles:][added: in a variety of ways, including:]

Rewritten

Our [removed: life science] [added: lab] properties, which contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry.

Rewritten

In addition to improvements funded by us as the landlord, many of our [removed: life science] [added: lab] tenants make significant investments to improve their leased space to accommodate biology, chemistry, or medical device research initiatives.

Rewritten

[removed: Life science] [added: Lab] properties are primarily configured in business park or campus settings and include multiple buildings.

Rewritten

Our properties are located in well-established geographical markets known for scientific research and drug discovery, including San Francisco [removed: (49%)] [added: (50%)] and San Diego [removed: (24%),] [added: (23%),] California, and Boston, Massachusetts [removed: (24%)] [added: (25%)] (based on total square feet).

Rewritten

At December 31, [removed: 2022, 92%] [added: 2023, 90%] of our [removed: life science] [added: lab] properties were triple-net leased (based on leased square feet).

Rewritten

The following table provides information about our most significant [removed: life science] [added: lab] tenant concentration for the year ended December 31, [removed: 2022:][added: 2023:]

Rewritten

Our [added: outpatient] medical [removed: office] segment includes [added: outpatient] medical [removed: office] buildings [removed: (MOBs)] and hospitals.

Rewritten

[removed: MOBs] [added: Outpatient medical buildings] typically contain physicians’ offices and examination rooms, and may also include pharmacies, hospital ancillary service space, and outpatient services such as diagnostic centers, rehabilitation clinics, and day-surgery operating rooms.

Rewritten

[removed: MOBs] [added: Outpatient medical buildings] are often built to accommodate higher structural loads for such specialized equipment and may contain vaults or other unique construction.

Rewritten

Our [removed: MOBs] [added: outpatient medical buildings] are typically multi-tenant properties leased to healthcare providers (hospitals and physician practices), with approximately 87% of our [removed: MOBs] [added: outpatient medical buildings] located on or adjacent to hospital campuses and 98% affiliated with hospital systems as of December 31, [removed: 2022] [added: 2023] (based on total square feet).

Rewritten

Occasionally, we invest in [removed: MOBs] [added: outpatient medical buildings] located on hospital campuses subject to ground leases.

Rewritten

At December 31, [removed: 2022,] [added: 2023,] approximately 65% of our [removed: MOBs] [added: outpatient medical buildings] were triple-net leased (based on leased square feet) with the remaining leased under gross or modified gross leases.

Rewritten

The following table provides information about our most significant [added: outpatient] medical [removed: office] tenant concentration for the year ended December 31, [removed: 2022:][added: 2023:]

Rewritten

Our [added: outpatient] medical [removed: office] segment also includes nine hospitals.

Rewritten

At December 31, [removed: 2022,] [added: 2023,] we had the following investments in our other non-reportable segments: (i) our unconsolidated joint venture with a sovereign wealth fund that owns 19 senior housing assets (which we refer to as our SWF SH [removed: JV),] [added: JV) and] (ii) loans [removed: receivable, and (iii) marketable debt securities.][added: receivable.]

Rewritten

Increased competition and resulting capitalization rate [removed: compression] [added: compression, as well as the impacts of inflation and higher interest rates,] make it more challenging for us to identify and successfully capitalize on opportunities that meet our objectives.

Rewritten

Income from our investments depends on our tenants’ and operators’ ability to compete with other companies on multiple levels, including: (i) the quality of care provided, (ii) reputation, (iii) success of product or drug development, (iv) price, (v) the range of services offered, (vi) the physical appearance of a [removed: facility,] [added: property,] (vii) alternatives for healthcare delivery, (viii) the supply of competing properties, (ix) physicians, (x) staff, (xi) referral sources, (xii) location, (xiii) the size and demographics of the population in surrounding areas, and (xiv) the financial condition of our tenants and operators.

New in FY2023

As noted above, we completed our Reorganization on February 10, 2023, and following that date, we hold substantially all of our assets and conduct our operations through the operating subsidiary, Healthpeak OP, LLC, a consolidated subsidiary of which we are the managing member.

New in FY2023

Our strategy is to invest in and manage real estate focused on healthcare discovery and delivery.

New in FY2023

These non-reportable segments have been presented on an aggregate basis herein.

New in FY2023

| Lab | | | | | | $ | 617,541 | | | | | 51.3 | | % | | | | 146 | | |

New in FY2023

| Outpatient medical | | | | | | 452,725 | | | | | | 37.6 | | % | | | | 297 | | |

New in FY2023

| CCRC | | | | | | 112,511 | | | | | | 9.3 | | % | | | | 15 | | |

New in FY2023

| | | | | | | $ | 1,204,987 | | | | | 100.0 | | % | | | | 477 | | |

New in FY2023

*The Merger Agreement*

New in FY2023

On October 29, 2023, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Physicians Realty Trust, Physicians Realty L.P. (the “Physicians Partnership”), and certain of our subsidiaries, pursuant to which, among other things, and through a series of transactions (the “Mergers”), (i) each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares to be canceled in accordance with the Merger Agreement) will be automatically converted into the right to receive 0.674 (the “Exchange Ratio”) shares of our common stock, and (ii) each outstanding common unit of the Physicians Partnership will be automatically converted into and become common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.

New in FY2023

Following the transactions contemplated in the Merger Agreement, the successor entities to Physicians Realty Trust and the Physicians Partnership will be direct and indirect subsidiaries of Healthpeak OP, respectively.

New in FY2023

In connection with the Mergers, we filed a Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”) on December 15, 2023, as amended on January 9, 2024, and a definitive joint proxy statement/prospectus for the Company and Physicians Realty Trust on January 11, 2024 in connection with our respective special meetings of stockholders and shareholders, as applicable, which will be held on February 21, 2024.

New in FY2023

Consummation of the Mergers are subject to the satisfaction or waiver of customary closing conditions, including the approval of our stockholders and the shareholders of Physicians Realty Trust.

New in FY2023

We expect the Mergers to close on March 1, 2024.

New in FY2023

If the Mergers are not consummated by July 31, 2024 (unless extended under certain circumstances), either we or Physicians Realty Trust may terminate the Merger Agreement.

New in FY2023

Our strategy is to invest in and manage real estate focused on healthcare discovery and delivery.

New in FY2023

Our portfolio is focused on lab and outpatient medical buildings, favorable sectors that benefit from the universal desire for improved health.

New in FY2023

We have built scale and fostered deep industry relationships, two unique factors that provide us with a competitive advantage.

New in FY2023

In addition, capital recycling through dispositions and redeployment through acquisitions, developments, and redevelopments is an important facet of our investment and financing strategies.

New in FY2023

We routinely have multiple transactions involving both individual properties and portfolios under consideration that are in varying stages of evaluation, underwriting, negotiation, and due diligence review, some of which, if consummated or completed, may have a material effect on our liquidity, results of operations, and financial condition.

New in FY2023

*Lab*

New in FY2023

*Outpatient Medical*

New in FY2023

Effective January 16, 2024, Medicare and Medicaid nursing facilities are required to disclose new data about the facility’s ownership, management, and the owners of real property lessors upon initial enrollment and revalidation.

New in FY2023

In addition, the nursing facilities are required to timely report any changes, including in connection with any change of ownership.

New in FY2023

The Centers for Medicare and Medicaid Services (“CMS”) defines the new disclosable parties to include members of the facility’s governing body, persons, or entities who are an officer, director, member, partner, trustee, or managing employee of the facility, persons, or entities that exercise operational, financial, or managerial control, lease or sublease real property to the facility, own a direct or indirect interest of five percent or greater of the real property, or provide management or administrative services to the facility.

New in FY2023

Additionally, facilities will be required to disclose whether any entity on the enrollment form is a private equity company or REIT.

New in FY2023

CMS will make the information publicly available.

New in FY2023

This new disclosure requirement involves reporting extensive information and may complicate our healthcare facility operators’ efforts to comply with Medicare and Medicaid requirements.

New in FY2023

Failure to comply with the new disclosure requirements could negatively affect our healthcare facility operators’ participation in Medicare and state Medicaid programs.

New in FY2023

- Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by *IR Magazine* and *Governance Intelligence*

New in FY2023

- Included in *Fortune*’s Best Workplaces in Real Estate list for the second consecutive year

New in FY2023

Base data utilized in the calculation of Scope 1 and Scope 2 GHG emissions is obtained from third-party invoices or estimates.

Dropped from FY2022

During 2020, we began the process of disposing of our senior housing triple-net and senior housing operating property (“SHOP”) portfolios.

Dropped from FY2022

In September 2021, we successfully completed the disposition of both portfolios.

Dropped from FY2022

| Life science | | | | | | $ | 552,533 | | | | | 50 | | % | | | | 149 | | |

Dropped from FY2022

| Medical office | | | | | | 432,969 | | | | | | 39 | | % | | | | 297 | | |

Dropped from FY2022

| CCRC | | | | | | 103,841 | | | | | | 9 | | % | | | | 15 | | |

Dropped from FY2022

| | | | | | | $ | 1,106,263 | | | | | 100 | | % | | | | 480 | | |

Dropped from FY2022

*UPREIT Reorganization*

Dropped from FY2022

On February 7, 2023, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with New Healthpeak, Inc., a Maryland corporation (“New Healthpeak”) and our wholly owned subsidiary, and Healthpeak Merger Sub, Inc., a Maryland corporation (“Merger Sub”) that is a wholly owned subsidiary of New Healthpeak.

Dropped from FY2022

The purpose of the transactions contemplated by the Merger Agreement is for us to implement a corporate reorganization into a new holding company structure commonly referred to as an Umbrella Partnership Real Estate Investment Trust, or UPREIT (the “Reorganization”).

Dropped from FY2022

Pursuant to the Merger Agreement, Merger Sub will merge with and into our company, with our company continuing as the surviving corporation and a wholly owned subsidiary of New Healthpeak (the “Merger”).

Dropped from FY2022

The Merger is expected to be effective as of February 10, 2023 (the “Effective Time”).

Dropped from FY2022

As part of the Merger, our name will change to Healthpeak Properties Interim, Inc., and, effective immediately after the Effective Time, New Healthpeak’s name will be changed to Healthpeak Properties, Inc. The Merger is expected to be conducted in accordance with Section 3-106.2 of the Maryland General Corporation Law.

Dropped from FY2022

Accordingly, the Merger will not require the approval of our stockholders, and the Merger will not give rise to statutory dissenters’ rights.

Dropped from FY2022

In connection with the Reorganization and immediately following the Merger, we will convert from a Maryland corporation to a Maryland limited liability company named Healthpeak OP, LLC (“Healthpeak OP”).

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

Following the Merger, the business, management and board of directors of New Healthpeak will be identical to the business, management and board of directors of our company immediately before the Merger, except that the business of the company is expected to be conducted exclusively through Healthpeak OP.

Dropped from FY2022

The consolidated assets and liabilities of New Healthpeak immediately following the Merger will be identical to the consolidated assets and liabilities of our company immediately prior to the Merger.

Dropped from FY2022

New Healthpeak will not hold any assets directly other than its ownership interest in Healthpeak OP and certain de minimis assets that may be held for certain administrative functions.

Dropped from FY2022

None of the properties owned by us or our subsidiaries or any interests therein will be transferred as part of the Reorganization.

Dropped from FY2022

All material indebtedness of our company immediately prior to the Merger will remain the indebtedness of Healthpeak OP after the Merger.

Dropped from FY2022

We focus on three purposely selected private pay asset classes—life science, medical office, and continuing care retirement community—to provide stability through inevitable market cycles.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

*Life science*

Dropped from FY2022

*Medical office*

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

- Named to *Fortune*’s inaugural Modern Board 25 list for the first time

Dropped from FY2022

- Named a *Wall Street Journal* Best-Managed Company for the first time

Dropped from FY2022

In 2021, we completed two green bond offerings with aggregate gross proceeds of $950 million.

Dropped from FY2022

The aggregate proceeds, net of discounts and debt issuance costs, of $938 million from the two green bonds have been allocated to eligible green projects.

Dropped from FY2022

Through our We Stand Together initiative, we launched numerous initiatives to help further our commitment to enhancing racial diversity and awareness, including augmenting recruiting practices to hire more diverse talent; implementing diversity, equity and inclusion training for senior leadership and employees; and sponsoring community outreach programs that support the education of underrepresented groups.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

An excerpt. Shown here: 40 of 61 rewritten, all 31 added and all 36 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2023 filing and the FY2022 filing.

Item 3. Legal Proceedings

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

See the “Legal Proceedings” section of Note [removed: 12] [added: 11] to the Consolidated Financial Statements for information regarding legal proceedings, which information is incorporated by reference in this Item 3.

Cover and table of contents

40 rewritten, 31 added, 14 removed, 88 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

For the fiscal year ended December 31, [removed: 2022][added: 2023]

Rewritten

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: [removed: $10.2] [added: $9.2] billion.

Rewritten

As of February [removed: 6, 2023,] [added: 7, 2024,] there were [removed: 546,782,509] [added: 547,172,983] shares of the registrant’s $1.00 par value common stock outstanding.

Rewritten

Portions of the definitive Proxy Statement for the registrant’s [removed: 2023] [added: 2024] Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission no later than 120 days after December 31, [removed: 2022,] [added: 2023,] have been incorporated by reference into Part III of this Report.

Rewritten

For the Fiscal Year Ended December 31, [removed: 2022][added: 2023]

Rewritten

| [Cautionary Language Regarding Forward-Looking [removed: Statements](#i0e89d5fc23c841beba74211ca606ff6b_10)] [added: Statements](#i39cdee5f0c374353affc19f158b4853c_10)] | | | | | | [removed: [1](#i0e89d5fc23c841beba74211ca606ff6b_10)] [added: [1](#i39cdee5f0c374353affc19f158b4853c_10)] | | |

Rewritten

| [Risk Factors [removed: Summary](#i0e89d5fc23c841beba74211ca606ff6b_13)] [added: Summary](#i39cdee5f0c374353affc19f158b4853c_13)] | | | | | | [removed: [1](#i0e89d5fc23c841beba74211ca606ff6b_13)] [added: [1](#i39cdee5f0c374353affc19f158b4853c_13)] | | |

Rewritten

| [Item [removed: 1.](#i0e89d5fc23c841beba74211ca606ff6b_19)] [added: 1.](#i39cdee5f0c374353affc19f158b4853c_19)] | | | [removed: [Business](#i0e89d5fc23c841beba74211ca606ff6b_19)] [added: [Business](#i39cdee5f0c374353affc19f158b4853c_19)] | | | [removed: [3](#i0e89d5fc23c841beba74211ca606ff6b_19)] [added: [4](#i39cdee5f0c374353affc19f158b4853c_19)] | | |

Rewritten

| [Item [removed: 1A.](#i0e89d5fc23c841beba74211ca606ff6b_22)] [added: 1A.](#i39cdee5f0c374353affc19f158b4853c_22)] | | | [Risk [removed: Factors](#i0e89d5fc23c841beba74211ca606ff6b_22)] [added: Factors](#i39cdee5f0c374353affc19f158b4853c_22)] | | | [removed: [12](#i0e89d5fc23c841beba74211ca606ff6b_22)] [added: [14](#i39cdee5f0c374353affc19f158b4853c_22)] | | |

Rewritten

| [Item [removed: 1B.](#i0e89d5fc23c841beba74211ca606ff6b_25)] [added: 1B.](#i39cdee5f0c374353affc19f158b4853c_25)] | | | [Unresolved Staff [removed: Comments](#i0e89d5fc23c841beba74211ca606ff6b_25)] [added: Comments](#i39cdee5f0c374353affc19f158b4853c_25)] | | | [removed: [29](#i0e89d5fc23c841beba74211ca606ff6b_25)] [added: [41](#i39cdee5f0c374353affc19f158b4853c_25)] | | |

Rewritten

| [Item [removed: 2.](#i0e89d5fc23c841beba74211ca606ff6b_28)] [added: 2.](#i39cdee5f0c374353affc19f158b4853c_28)] | | | [removed: [Properties](#i0e89d5fc23c841beba74211ca606ff6b_28)] [added: [Properties](#i39cdee5f0c374353affc19f158b4853c_28)] | | | [removed: [29](#i0e89d5fc23c841beba74211ca606ff6b_28)] [added: [42](#i39cdee5f0c374353affc19f158b4853c_28)] | | |

Rewritten

| [Item [removed: 3.](#i0e89d5fc23c841beba74211ca606ff6b_31)] [added: 3.](#i39cdee5f0c374353affc19f158b4853c_31)] | | | [Legal [removed: Proceedings](#i0e89d5fc23c841beba74211ca606ff6b_31)] [added: Proceedings](#i39cdee5f0c374353affc19f158b4853c_31)] | | | [removed: [32](#i0e89d5fc23c841beba74211ca606ff6b_31)] [added: [45](#i39cdee5f0c374353affc19f158b4853c_31)] | | |

Rewritten

| [Item [removed: 4.](#i0e89d5fc23c841beba74211ca606ff6b_34)] [added: 4.](#i39cdee5f0c374353affc19f158b4853c_34)] | | | [Mine Safety [removed: Disclosures](#i0e89d5fc23c841beba74211ca606ff6b_34)] [added: Disclosures](#i39cdee5f0c374353affc19f158b4853c_34)] | | | [removed: [32](#i0e89d5fc23c841beba74211ca606ff6b_34)] [added: [45](#i39cdee5f0c374353affc19f158b4853c_34)] | | |

Rewritten

| [Item [removed: 5.](#i0e89d5fc23c841beba74211ca606ff6b_40)] [added: 5.](#i39cdee5f0c374353affc19f158b4853c_40)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i0e89d5fc23c841beba74211ca606ff6b_40)] [added: Securities](#i39cdee5f0c374353affc19f158b4853c_40)] | | | [removed: [33](#i0e89d5fc23c841beba74211ca606ff6b_40)] [added: [46](#i39cdee5f0c374353affc19f158b4853c_40)] | | |

Rewritten

| [Item [removed: 6.](#i0e89d5fc23c841beba74211ca606ff6b_43)] [added: 6.](#i39cdee5f0c374353affc19f158b4853c_43)] | | | [removed: [\[Reserved\]](#i0e89d5fc23c841beba74211ca606ff6b_43)] [added: [\[Reserved\]](#i39cdee5f0c374353affc19f158b4853c_43)] | | | [removed: [36](#i0e89d5fc23c841beba74211ca606ff6b_43)] [added: [49](#i39cdee5f0c374353affc19f158b4853c_43)] | | |

Rewritten

| [Item [removed: 7.](#i0e89d5fc23c841beba74211ca606ff6b_46)] [added: 7.](#i39cdee5f0c374353affc19f158b4853c_46)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i0e89d5fc23c841beba74211ca606ff6b_46)] [added: Operations](#i39cdee5f0c374353affc19f158b4853c_46)] | | | [removed: [36](#i0e89d5fc23c841beba74211ca606ff6b_46)] [added: [49](#i39cdee5f0c374353affc19f158b4853c_46)] | | |

Rewritten

| [Item [removed: 7A.](#i0e89d5fc23c841beba74211ca606ff6b_94)] [added: 7A.](#i39cdee5f0c374353affc19f158b4853c_94)] | | | [Quantitative and Qualitative Disclosures About Market [removed: Risk](#i0e89d5fc23c841beba74211ca606ff6b_94)] [added: Risk](#i39cdee5f0c374353affc19f158b4853c_94)] | | | [removed: [57](#i0e89d5fc23c841beba74211ca606ff6b_94)] [added: [68](#i39cdee5f0c374353affc19f158b4853c_94)] | | |

Rewritten

| [Item [removed: 8.](#i0e89d5fc23c841beba74211ca606ff6b_97)] [added: 8.](#i39cdee5f0c374353affc19f158b4853c_97)] | | | [Financial Statements and Supplementary [removed: Data](#i0e89d5fc23c841beba74211ca606ff6b_97)] [added: Data](#i39cdee5f0c374353affc19f158b4853c_97)] | | | [removed: [58](#i0e89d5fc23c841beba74211ca606ff6b_97)] [added: [69](#i39cdee5f0c374353affc19f158b4853c_97)] | | |

Rewritten

| [Item [removed: 9.](#i0e89d5fc23c841beba74211ca606ff6b_214)] [added: 9.](#i39cdee5f0c374353affc19f158b4853c_214)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i0e89d5fc23c841beba74211ca606ff6b_214)] [added: Disclosure](#i39cdee5f0c374353affc19f158b4853c_214)] | | | [removed: [127](#i0e89d5fc23c841beba74211ca606ff6b_214)] [added: [136](#i39cdee5f0c374353affc19f158b4853c_214)] | | |

Rewritten

| [Item [removed: 9A.](#i0e89d5fc23c841beba74211ca606ff6b_217)] [added: 9A.](#i39cdee5f0c374353affc19f158b4853c_217)] | | | [Controls and [removed: Procedures](#i0e89d5fc23c841beba74211ca606ff6b_217)] [added: Procedures](#i39cdee5f0c374353affc19f158b4853c_217)] | | | [removed: [127](#i0e89d5fc23c841beba74211ca606ff6b_217)] [added: [136](#i39cdee5f0c374353affc19f158b4853c_217)] | | |

Rewritten

| [Item [removed: 9B.](#i0e89d5fc23c841beba74211ca606ff6b_223)] [added: 9B.](#i39cdee5f0c374353affc19f158b4853c_223)] | | | [Other [removed: Information](#i0e89d5fc23c841beba74211ca606ff6b_223)] [added: Information](#i39cdee5f0c374353affc19f158b4853c_223)] | | | [removed: [129](#i0e89d5fc23c841beba74211ca606ff6b_223)] [added: [138](#i39cdee5f0c374353affc19f158b4853c_223)] | | |

Rewritten

| [Item [removed: 9C.](#i0e89d5fc23c841beba74211ca606ff6b_226)] [added: 9C.](#i39cdee5f0c374353affc19f158b4853c_226)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i0e89d5fc23c841beba74211ca606ff6b_226)] [added: Inspections](#i39cdee5f0c374353affc19f158b4853c_226)] | | | [removed: [129](#i0e89d5fc23c841beba74211ca606ff6b_226)] [added: [138](#i39cdee5f0c374353affc19f158b4853c_226)] | | |

Rewritten

| [Part [removed: III](#i0e89d5fc23c841beba74211ca606ff6b_229)] [added: III](#i39cdee5f0c374353affc19f158b4853c_229)] | | | | | | [removed: [130](#i0e89d5fc23c841beba74211ca606ff6b_229)] [added: [139](#i39cdee5f0c374353affc19f158b4853c_229)] | | |

Rewritten

| [Item [removed: 10.](#i0e89d5fc23c841beba74211ca606ff6b_232)] [added: 10.](#i39cdee5f0c374353affc19f158b4853c_232)] | | | [Directors, Executive [removed: Officers,] [added: Officers] and Corporate [removed: Governance](#i0e89d5fc23c841beba74211ca606ff6b_232)] [added: Governance](#i39cdee5f0c374353affc19f158b4853c_232)] | | | [removed: [130](#i0e89d5fc23c841beba74211ca606ff6b_232)] [added: [139](#i39cdee5f0c374353affc19f158b4853c_232)] | | |

Rewritten

| [Item [removed: 11.](#i0e89d5fc23c841beba74211ca606ff6b_235)] [added: 11.](#i39cdee5f0c374353affc19f158b4853c_235)] | | | [Executive [removed: Compensation](#i0e89d5fc23c841beba74211ca606ff6b_235)] [added: Compensation](#i39cdee5f0c374353affc19f158b4853c_235)] | | | [removed: [130](#i0e89d5fc23c841beba74211ca606ff6b_235)] [added: [139](#i39cdee5f0c374353affc19f158b4853c_235)] | | |

Rewritten

| [Item [removed: 12.](#i0e89d5fc23c841beba74211ca606ff6b_238)] [added: 12.](#i39cdee5f0c374353affc19f158b4853c_238)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i0e89d5fc23c841beba74211ca606ff6b_238)] [added: Matters](#i39cdee5f0c374353affc19f158b4853c_238)] | | | [removed: [130](#i0e89d5fc23c841beba74211ca606ff6b_238)] [added: [139](#i39cdee5f0c374353affc19f158b4853c_238)] | | |

Rewritten

| [Item [removed: 13.](#i0e89d5fc23c841beba74211ca606ff6b_241)] [added: 13.](#i39cdee5f0c374353affc19f158b4853c_241)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i0e89d5fc23c841beba74211ca606ff6b_241)] [added: Independence](#i39cdee5f0c374353affc19f158b4853c_241)] | | | [removed: [130](#i0e89d5fc23c841beba74211ca606ff6b_241)] [added: [139](#i39cdee5f0c374353affc19f158b4853c_241)] | | |

Rewritten

| [Item [removed: 14.](#i0e89d5fc23c841beba74211ca606ff6b_244)] [added: 14.](#i39cdee5f0c374353affc19f158b4853c_244)] | | | [Principal Accountant Fees and [removed: Services](#i0e89d5fc23c841beba74211ca606ff6b_244)] [added: Services](#i39cdee5f0c374353affc19f158b4853c_244)] | | | [removed: [130](#i0e89d5fc23c841beba74211ca606ff6b_244)] [added: [139](#i39cdee5f0c374353affc19f158b4853c_244)] | | |

Rewritten

| [Item [removed: 15.](#i0e89d5fc23c841beba74211ca606ff6b_250)] [added: 15.](#i39cdee5f0c374353affc19f158b4853c_250)] | | | [Exhibits and Financial Statement [removed: Schedules](#i0e89d5fc23c841beba74211ca606ff6b_250)] [added: Schedules](#i39cdee5f0c374353affc19f158b4853c_250)] | | | [removed: [131](#i0e89d5fc23c841beba74211ca606ff6b_250)] [added: [140](#i39cdee5f0c374353affc19f158b4853c_250)] | | |

Rewritten

| [Item [removed: 16.](#i0e89d5fc23c841beba74211ca606ff6b_256)] [added: 16.](#i39cdee5f0c374353affc19f158b4853c_256)] | | | [Form 10-K [removed: Summary](#i0e89d5fc23c841beba74211ca606ff6b_256)] [added: Summary](#i39cdee5f0c374353affc19f158b4853c_256)] | | | [removed: [135](#i0e89d5fc23c841beba74211ca606ff6b_256)] [added: [144](#i39cdee5f0c374353affc19f158b4853c_256)] | | |

Rewritten

*All references in this report to “Healthpeak,” the “Company,” “we,” [removed: “us”] [added: “us,”] or “our” mean Healthpeak Properties, Inc., together with its consolidated subsidiaries.

Rewritten

- macroeconomic trends, including inflation, interest rates, [added: construction and] labor costs, and unemployment;

Rewritten

- our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in [removed: a] [added: that] specific sector than if we invested across multiple sectors;

Rewritten

- our property development, redevelopment, and tenant improvement [removed: activity] risks, including project abandonments, project delays, and lower profits than expected;

Rewritten

- significant regulation, funding requirements, and uncertainty faced by our [removed: life science] [added: lab] tenants;

Rewritten

- the ability of the hospitals on whose campuses our [added: outpatient] medical [removed: office] buildings [removed: (“MOBs”)] are located and their affiliated healthcare systems to remain competitive or financially viable;

Rewritten

- [added: human capital risks, including] the loss or limited availability of our key personnel;

Rewritten

- the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, [removed: volatility] [added: bank failures] or [removed: uncertainty in the capital markets,] [added: other events affecting financial institutions,] and other factors;

Rewritten

- ownership limits in our charter that restrict ownership in our stock; [removed: and]

Rewritten

- provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our [removed: stockholders.][added: stockholders;]

New in FY2023

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

New in FY2023

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

New in FY2023

| [Important Information Regarding Our Disclosure to Investors](#i39cdee5f0c374353affc19f158b4853c_2048) | | | | | | [3](#i39cdee5f0c374353affc19f158b4853c_2048) | | |

New in FY2023

| [Part I](#i39cdee5f0c374353affc19f158b4853c_16) | | | | | | [4](#i39cdee5f0c374353affc19f158b4853c_16) | | |

New in FY2023

| [I](#i39cdee5f0c374353affc19f158b4853c_2012)[tem 1C.](#i39cdee5f0c374353affc19f158b4853c_2012) | | | [C](#i39cdee5f0c374353affc19f158b4853c_2012)[ybersecurity](#i39cdee5f0c374353affc19f158b4853c_2012) | | | [41](#i39cdee5f0c374353affc19f158b4853c_2012) | | |

New in FY2023

| [Part II](#i39cdee5f0c374353affc19f158b4853c_37) | | | | | | [46](#i39cdee5f0c374353affc19f158b4853c_37) | | |

New in FY2023

| [Part IV](#i39cdee5f0c374353affc19f158b4853c_247) | | | | | | [140](#i39cdee5f0c374353affc19f158b4853c_247) | | |

New in FY2023

| | | | [Signatures](#i39cdee5f0c374353affc19f158b4853c_259) | | | [145](#i39cdee5f0c374353affc19f158b4853c_259) | | |

New in FY2023

*On February 10, 2023, we completed our corporate reorganization (the “Reorganization”) into an umbrella partnership REIT (“UPREIT”).

New in FY2023

Substantially all of our business is conducted through Healthpeak OP, LLC (“Healthpeak OP”).

New in FY2023

We are the managing member of Healthpeak OP and do not have material assets or liabilities, other than through our investment in Healthpeak OP.*

New in FY2023

Forward-looking statements in this Annual Report on Form 10-K include statements regarding the proposed transactions involving Healthpeak and Physicians Realty Trust (as discussed in further detail in this report), including but not limited to, statements about the anticipated benefits of the proposed transactions involving Healthpeak and Physicians Realty Trust, as well as statements regarding future financial and operating results, plans, objectives, expectations, and intentions.

New in FY2023

- risks associated with the Mergers (as defined below), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all; potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers; and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers;

New in FY2023

- our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame;

New in FY2023

- changes within the industries in which we operate;

New in FY2023

- factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us;

New in FY2023

- the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers;

New in FY2023

- our use of joint ventures may limit our returns on and our flexibility with jointly owned investments;

New in FY2023

- any requirement that we recognize reserves, allowances, credit losses, or impairment charges;

New in FY2023

- environmental, social, and governance (“ESG”) and sustainability commitments and requirements, as well as stakeholder expectations;

New in FY2023

- our reliance on information technology systems and any material failure, inadequacy, interruption, or security failure of that technology;

New in FY2023

- volatility, disruption, or uncertainty in the financial markets;

New in FY2023

- our taxable REIT subsidiaries being subject to corporate level tax;

New in FY2023

- tax imposed on any net income from “prohibited transactions”;

New in FY2023

- conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP common units;

New in FY2023

- provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; and

New in FY2023

- our status as a holding company of Healthpeak OP.

New in FY2023

Important Information Regarding Our Disclosure to Investors

New in FY2023

We may use our website (www.healthpeak.com) and our LinkedIn account (https://www.linkedin.com/company/healthpeak) to communicate with our investors and disclose company information.

New in FY2023

The information disclosed through those channels may be considered to be material, so investors should monitor them in addition to our press releases, SEC filings, and public conference calls and webcasts.

New in FY2023

The contents of our website or social media channels referenced herein are not incorporated by reference into this Annual Report on Form 10-K.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

| [Part I](#i0e89d5fc23c841beba74211ca606ff6b_16) | | | | | | [3](#i0e89d5fc23c841beba74211ca606ff6b_16) | | |

Dropped from FY2022

| [Part II](#i0e89d5fc23c841beba74211ca606ff6b_37) | | | | | | [33](#i0e89d5fc23c841beba74211ca606ff6b_37) | | |

Dropped from FY2022

| [Part IV](#i0e89d5fc23c841beba74211ca606ff6b_247) | | | | | | [131](#i0e89d5fc23c841beba74211ca606ff6b_247) | | |

Dropped from FY2022

| | | | [Signatures](#i0e89d5fc23c841beba74211ca606ff6b_259) | | | [136](#i0e89d5fc23c841beba74211ca606ff6b_259) | | |

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

- the ability of our existing and future tenants, operators, and borrowers to conduct their respective businesses in a manner that generates sufficient income to make rent and loan payments to us;

Dropped from FY2022

- the financial condition of our tenants, operators, and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings;

Dropped from FY2022

- changes within the life science industry;

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

- our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation;

Dropped from FY2022

- our reliance on information technology systems and the potential impact of system failures, disruptions, or breaches;

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Item 1C. Cybersecurity

0 rewritten, 28 added, 0 removed, 0 unchanged

New section this year

Read the full itemFY2023 item · filed February 9, 2024

New in FY2023

Cybersecurity Risk Management and Strategy

New in FY2023

In our business operations, we use information technology, enterprise applications, communications tools, cloud network solutions, and related systems to manage our operations, including to manage our building systems, tenant and vendor relationships, accounting and recordkeeping, and communications, among other aspects of our business.

New in FY2023

We have developed and implemented a cybersecurity risk management program intended to protect our properties, confidential and proprietary data, and information technology and systems, from cybersecurity threats, including unauthorized access or attack.

New in FY2023

We leverage the National Institute of Standards and Technology (“NIST”) Cybersecurity Framework as a guide to help us identify, assess, and manage cybersecurity risks relevant to the business.

New in FY2023

This does not imply that we meet any particular technical standards, specifications, or requirements.

New in FY2023

Our processes for assessing, identifying, and managing risks from cybersecurity threats, including operational risks, financial reporting risks, reputational risks, personal data theft, fraud, and other potential risks, are integrated into our overall enterprise risk management process, and share common methodologies, reporting channels, and governance processes that apply across the enterprise risk management process to other legal, compliance, strategic, operational, and financial risk areas.

New in FY2023

Our cybersecurity risk management program includes the following:

New in FY2023

- a multidisciplinary team comprised of personnel from information technology (“IT”), internal audit, accounting, and legal, as well as third-party cybersecurity experts principally responsible for directing (i) our cybersecurity risk assessment processes, (ii) our security processes, and (iii) our response to cybersecurity incidents;

New in FY2023

- risk assessments designed to help identify material cybersecurity risks to our critical systems, information, services, and our broader enterprise IT environment;

New in FY2023

- internal and third-party security tools to monitor our systems, identify cybersecurity risks, and test our IT environment;

New in FY2023

- the use of third-party cybersecurity experts, where appropriate, to assess, test or otherwise assist with aspects of our security processes;

New in FY2023

- a cybersecurity incident response plan and business continuity plan;

New in FY2023

- cybersecurity training for employees and key business partners with access to our systems;

New in FY2023

- a third-party cybersecurity risk management process for service providers and vendors who access our systems;

New in FY2023

- requiring employees, as well as third parties who have access to our systems, to treat confidential and private information and data with care, including performing controls relating to such data; and

New in FY2023

- cybersecurity risk insurance.

New in FY2023

We also seek to engage reputable service providers that maintain cybersecurity programs or controls.

New in FY2023

We have not identified risks from known cybersecurity threats within the prior fiscal year, including as a result of any prior cybersecurity incident, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.

New in FY2023

Please refer to “Item 1A, Risk Factors” in this report for additional information about certain ongoing risks related to our information technology that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.

New in FY2023

Cybersecurity Governance

New in FY2023

Cybersecurity is an important part of our overall risk management processes and an area of focus for our Board of Directors and management.

New in FY2023

The Board, in coordination with the Audit Committee, oversees the Company’s enterprise risk management process, including the management of material risks arising from cybersecurity threats.

New in FY2023

The Audit Committee regularly receives updates from management and third-party cybersecurity experts about major cybersecurity risks, their potential impact on our business operations, and management’s processes to identify, monitor, and mitigate such risks, including, as relevant, the results of assessments or audits of our processes.

New in FY2023

The Audit Committee periodically provides updates on these matters to the Board of Directors.

New in FY2023

Our enterprise risk team consists of cross-functional professionals who collaborate with subject matter specialists, as necessary, including an independent third-party expert we have retained to functionally serve as a virtual chief information security officer (“CISO”), to identify and assess material risks from cybersecurity threats, their severity, and potential mitigation steps.

New in FY2023

The CISO is primarily responsible for leading our cybersecurity risk assessment and management processes.

New in FY2023

This expert has experience having served as the chief information security officer for an international commercial real estate services company and currently serves as chief executive officer of a cybersecurity firm focused on commercial real estate.

New in FY2023

He is supported by an internal cross-functional management team of IT and internal audit personnel who regularly review and assess cybersecurity initiatives, including our incident response plan, as well as cybersecurity compliance, training and risk management efforts.

Item 2. Properties

23 rewritten, 31 added, 31 removed, 33 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

The following table summarizes our consolidated property [removed: and direct financing lease (“DFL”) investments, excluding] investments [removed: classified] as [removed: discontinued operations, as] of and for the year ended December 31, [removed: 2022] [added: 2023] (square feet and dollars in thousands):

Rewritten

| Facility Location | | | | | | Number of Facilities | | | | | | Capacity(1) | | | | | | Gross Asset Value(2) | | | | | | Real Estate Revenues(3) | | | | | | [removed: Operating Expenses] [added: Operating Expenses(4)] | | |

Rewritten

| [removed: *Life science:*] [added: *Lab:*] | | | | | | | | | | | | *(Sq. Ft.)* | | | | | | | | | | | | | | | | | | | | |

Rewritten

| [removed: *Medical office:*] [added: *Outpatient medical:*] | | | | | | | | | | | | *(Sq. Ft.)* | | | | | | | | | | | | | | | | | | | | |

Rewritten

(3)Represents the combined amount of rental and related revenues, resident fees and services, [removed: income from DFLs,] and government grant income.

Rewritten

The following table summarizes occupancy and average annual rent trends for our consolidated property and [removed: DFL] investments [added: held under a direct financing lease (“DFL”)] for the years ended December 31 (average occupied square feet in thousands):

Rewritten

| | | | [removed: 2022] [added: 2023] | | | | | | [removed: 2021] [added: 2022] | | | | | | [removed: 2020] [added: 2021] | | | | | | | | | | | | | | |

Rewritten

| Average occupancy percentage | | | 98 | | % | | | | [removed: 97] [added: 98] | | % | | | | [removed: 96] [added: 97] | | % | | | | | | | | | | | | |

Rewritten

| Average annual rent per square foot(1) | | | $ | [removed: 71] [added: 82] | | | | | $ | [removed: 66] [added: 71] | | | | | $ | [removed: 63] [added: 66] | | | | | | | | | | | | | |

Rewritten

| Average occupied square feet | | | [removed: 10,610] [added: 10,334] | | | | | | [removed: 10,143] [added: 10,610] | | | | | | [removed: 8,714] [added: 10,143] | | | | | | | | | | | | | | |

Rewritten

| Average occupancy percentage | | | 90 | | % | | | | 90 | | % | | | | [removed: 91] [added: 90] | | % | | | | | | | | | | | | |

Rewritten

| Average annual rent per square foot(1) | | | $ | [removed: 33] [added: 35] | | | | | $ | [removed: 31] [added: 33] | | | | | $ | [removed: 30] [added: 31] | | | | | | | | | | | | | |

Rewritten

| Average occupied square feet | | | [removed: 21,472] [added: 21,337] | | | | | | [removed: 21,046] [added: 21,472] | | | | | | [removed: 20,225] [added: 21,046] | | | | | | | | | | | | | | |

Rewritten

| Average occupancy percentage | | | [removed: 82] [added: 84] | | % | | | | [removed: 79] [added: 82] | | % | | | | [removed: 81] [added: 79] | | % | | | | | | | | | | | | |

Rewritten

| Average annual rent per occupied [removed: unit(1)] [added: unit(3)] | | | $ | [removed: 84,664] [added: 88,524] | | | | | $ | [removed: 80,391] [added: 84,664] | | | | | $ | [removed: 80,772] [added: 80,391] | | | | | | | | | | | | | |

Rewritten

| Average occupied units | | | [removed: 5,926] [added: 5,960] | | | | | | [removed: 5,881] [added: 5,926] | | | | | | [removed: 5,605] [added: 5,881] | | | | | | | | | | | | | | |

Rewritten

[removed: (1)Average annual rent is presented] [added: (1)Presented] as a ratio of revenues comprised of rental and related [removed: revenues, resident fees] [added: revenues] and [removed: services,] income from [removed: DFLs, and government grant income] [added: DFLs] divided by [removed: the] average occupied square feet [removed: or average occupied units of the facilities] and annualized for acquisitions for the year in which they occurred.

Rewritten

Average annual rent excludes termination fees and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, [added: and] DFL non-cash [removed: interest, and the impact of deferred community fee income).][added: interest).]

Rewritten

The following table shows tenant lease expirations for the next 10 years and thereafter at our consolidated properties, assuming that none of the tenants exercise any of their renewal or purchase options, and excludes properties in our CCRC segment and assets held for sale as of December 31, [removed: 2022] [added: 2023] (dollars and square feet in thousands):

Rewritten

| Segment | | | | | | Total | | | | | | [removed: 2023(1) | | | | | | 2024] [added: 2024(1)] | | | | | | 2025 | | | | | | 2026 | | | | | | 2027 | | | | | | 2028 | | | | | | 2029 | | | | | | 2030 | | | | | | 2031 | | | | | | 2032 | | | | | | [added: 2033 | | | | | |] Thereafter | | |

Rewritten

| % of segment base rent | | | | | | 100 | | | | | | [removed: 5] [added: 6] | | | | | | [removed: 5] [added: 8] | | | | | | [removed: 9] [added: 5] | | | | | | [removed: 5] [added: 11] | | | | | | [removed: 12] [added: 6] | | | | | | [removed: 6] [added: 8] | | | | | | [removed: 9] [added: 16] | | | | | | 14 | | | | | | [removed: 14] [added: 9] | | | | | | [removed: 8] [added: 6] | | | | | | [removed: 13] [added: 11] | | |

Rewritten

| % of segment base rent | | | | | | 100 | | | | | | [removed: 13] [added: 16] | | | | | | 13 | | | | | | [removed: 18] [added: 11] | | | | | | 9 | | | | | | [removed: 9] [added: 10] | | | | | | 7 | | | | | | [removed: 6] [added: 7] | | | | | | [removed: 6] [added: 7] | | | | | | [removed: 7] [added: 5] | | | | | | 5 | | | | | | [removed: 7] [added: 10] | | |

Rewritten

| % of total base rent | | | | | | 100 | | | | | | [removed: 9] [added: 11] | | | | | | [removed: 9] [added: 10] | | | | | | [removed: 13] [added: 8] | | | | | | [removed: 7] [added: 10] | | | | | | [removed: 11] [added: 8] | | | | | | [removed: 7] [added: 8] | | | | | | [removed: 8] [added: 11] | | | | | | [removed: 10] [added: 11] | | | | | | [removed: 10] [added: 7] | | | | | | [removed: 6] [added: 5] | | | | | | [removed: 10] [added: 11] | | |

New in FY2023

Our strategy is to invest in and manage real estate focused on healthcare discovery and delivery.

New in FY2023

| California | | | | | | 115 | | | | | | 8,094 | | | | | | $ | 5,869,665 | | | | | $ | 629,657 | | | | | $ | (157,795) | |

New in FY2023

| Massachusetts | | | | | | 19 | | | | | | 2,613 | | | | | | 2,795,913 | | | | | | 240,029 | | | | | | (70,259) | | |

New in FY2023

| Other (1 State) | | | | | | 4 | | | | | | 240 | | | | | | 54,236 | | | | | | 8,640 | | | | | | (1,576) | | |

New in FY2023

| *Total lab* | | | | | | 138 | | | | | | 10,947 | | | | | | $ | 8,719,814 | | | | | $ | 878,326 | | | | | $ | (229,630) | |

New in FY2023

| Texas | | | | | | 75 | | | | | | 7,638 | | | | | | $ | 1,549,757 | | | | | $ | 220,805 | | | | | $ | (75,159) | |

New in FY2023

| Pennsylvania | | | | | | 4 | | | | | | 1,270 | | | | | | 367,434 | | | | | | 34,321 | | | | | | (15,603) | | |

New in FY2023

| Colorado | | | | | | 19 | | | | | | 1,311 | | | | | | 362,822 | | | | | | 47,697 | | | | | | (18,366) | | |

New in FY2023

| California | | | | | | 15 | | | | | | 862 | | | | | | 355,026 | | | | | | 40,057 | | | | | | (17,206) | | |

New in FY2023

| South Carolina | | | | | | 18 | | | | | | 1,105 | | | | | | 340,073 | | | | | | 27,851 | | | | | | (5,315) | | |

New in FY2023

| Florida | | | | | | 25 | | | | | | 1,438 | | | | | | 309,246 | | | | | | 41,609 | | | | | | (14,994) | | |

New in FY2023

| Other (29 States) | | | | | | 139 | | | | | | 9,977 | | | | | | 2,586,334 | | | | | | 341,139 | | | | | | (116,489) | | |

New in FY2023

| *Total outpatient medical* | | | | | | 295 | | | | | | 23,601 | | | | | | $ | 5,870,692 | | | | | $ | 753,479 | | | | | $ | (263,132) | |

New in FY2023

| Florida | | | | | | 9 | | | | | | 4,783 | | | | | | $ | 1,398,609 | | | | | $ | 343,971 | | | | | $ | (275,781) | |

New in FY2023

| Other (5 States) | | | | | | 6 | | | | | | 2,314 | | | | | | 631,199 | | | | | | 183,630 | | | | | | (137,691) | | |

New in FY2023

| *Total CCRC* | | | | | | 15 | | | | | | 7,097 | | | | | | $ | 2,029,808 | | | | | $ | 527,601 | | | | | $ | (413,472) | |

New in FY2023

| Total properties | | | | | | 448 | | | | | | | | | | | | $ | 16,620,314 | | | | | $ | 2,159,406 | | | | | $ | (906,234) | |

New in FY2023

Excludes gross real estate of $123 million related to two lab buildings and one outpatient medical building classified as held for sale.

New in FY2023

(4)Excludes operating expenses related to corporate non-segment assets (see Note 15 to the Consolidated Financial Statements).

New in FY2023

| *Lab:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2023

| *Outpatient medical(2):* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2023

(2)During the first quarter of 2022, we sold our remaining hospital under a DFL.

New in FY2023

(3)Presented as a ratio of revenues comprised of resident fees and services and government grant income divided by average occupied units of the facilities.

New in FY2023

Average annual rent excludes termination fees and non-cash revenue adjustments (i.e., the impact of deferred community fee income).

New in FY2023

| *Lab:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2023

| Square feet | | | | | | 10,303 | | | | | | 537 | | | | | | 1,065 | | | | | | 618 | | | | | | 1,407 | | | | | | 681 | | | | | | 806 | | | | | | 1,334 | | | | | | 1,393 | | | | | | 866 | | | | | | 531 | | | | | | 1,065 | | |

New in FY2023

| Base rent(2) | | | | | | $ | 608,770 | | | | | $ | 36,709 | | | | | $ | 50,557 | | | | | $ | 30,694 | | | | | $ | 66,918 | | | | | $ | 36,728 | | | | | $ | 50,104 | | | | | $ | 94,051 | | | | | $ | 84,727 | | | | | $ | 55,504 | | | | | $ | 36,642 | | | | | $ | 66,136 | |

New in FY2023

| *Outpatient medical:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2023

| Square feet | | | | | | 21,414 | | | | | | 2,848 | | | | | | 2,830 | | | | | | 2,049 | | | | | | 1,870 | | | | | | 2,539 | | | | | | 1,419 | | | | | | 1,310 | | | | | | 1,637 | | | | | | 1,357 | | | | | | 918 | | | | | | 2,637 | | |

New in FY2023

| Base rent(2) | | | | | | $ | 546,589 | | | | | $ | 85,359 | | | | | $ | 68,994 | | | | | $ | 57,376 | | | | | $ | 51,438 | | | | | $ | 56,996 | | | | | $ | 38,197 | | | | | $ | 36,069 | | | | | $ | 40,803 | | | | | $ | 28,096 | | | | | $ | 27,376 | | | | | $ | 55,885 | |

New in FY2023

| Base rent(2) | | | | | | $ | 1,155,359 | | | | | $ | 122,068 | | | | | $ | 119,551 | | | | | $ | 88,070 | | | | | $ | 118,356 | | | | | $ | 93,724 | | | | | $ | 88,301 | | | | | $ | 130,120 | | | | | $ | 125,530 | | | | | $ | 83,600 | | | | | $ | 64,018 | | | | | $ | 122,021 | |

Dropped from FY2022

We are organized to invest in income-producing healthcare-related facilities.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

| California | | | | | | 116 | | | | | | 7,829 | | | | | | $ | 5,687,333 | | | | | $ | 596,288 | | | | | $ | (144,384) | |

Dropped from FY2022

| Massachusetts | | | | | | 19 | | | | | | 2,613 | | | | | | 2,750,357 | | | | | | 204,828 | | | | | | (61,506) | | |

Dropped from FY2022

| Other (2 States) | | | | | | 6 | | | | | | 240 | | | | | | 54,236 | | | | | | 16,457 | | | | | | (3,253) | | |

Dropped from FY2022

| *Total life science* | | | | | | 141 | | | | | | 10,682 | | | | | | $ | 8,491,926 | | | | | $ | 817,573 | | | | | $ | (209,143) | |

Dropped from FY2022

| Texas | | | | | | 73 | | | | | | 7,601 | | | | | | $ | 1,514,204 | | | | | $ | 212,591 | | | | | $ | (72,310) | |

Dropped from FY2022

| Pennsylvania | | | | | | 4 | | | | | | 1,270 | | | | | | 364,825 | | | | | | 33,764 | | | | | | (14,913) | | |

Dropped from FY2022

| California | | | | | | 15 | | | | | | 861 | | | | | | 352,279 | | | | | | 39,458 | | | | | | (18,036) | | |

Dropped from FY2022

| South Carolina | | | | | | 18 | | | | | | 1,105 | | | | | | 344,915 | | | | | | 27,124 | | | | | | (5,188) | | |

Dropped from FY2022

| Colorado | | | | | | 18 | | | | | | 1,311 | | | | | | 344,223 | | | | | | 43,220 | | | | | | (16,631) | | |

Dropped from FY2022

| Florida | | | | | | 26 | | | | | | 1,553 | | | | | | 316,166 | | | | | | 42,949 | | | | | | (15,892) | | |

Dropped from FY2022

| Other (29 States)(4) | | | | | | 140 | | | | | | 10,006 | | | | | | 2,546,560 | | | | | | 326,264 | | | | | | (110,339) | | |

Dropped from FY2022

| *Total medical office* | | | | | | 294 | | | | | | 23,707 | | | | | | $ | 5,783,172 | | | | | $ | 725,370 | | | | | $ | (253,309) | |

Dropped from FY2022

| Florida | | | | | | 9 | | | | | | 4,881 | | | | | | $ | 1,330,325 | | | | | $ | 332,601 | | | | | $ | (272,629) | |

Dropped from FY2022

| Other (5 States) | | | | | | 6 | | | | | | 2,302 | | | | | | 606,198 | | | | | | 169,099 | | | | | | (127,910) | | |

Dropped from FY2022

| *Total CCRC* | | | | | | 15 | | | | | | 7,183 | | | | | | $ | 1,936,523 | | | | | $ | 501,700 | | | | | $ | (400,539) | |

Dropped from FY2022

| Total properties | | | | | | 450 | | | | | | | | | | | | $ | 16,211,621 | | | | | $ | 2,044,643 | | | | | $ | (862,991) | |

Dropped from FY2022

Excludes gross real estate related to life science assets held for sale of $68 million.

Dropped from FY2022

(4)Real estate revenues includes income from DFLs for one leased property classified as a DFL which was sold during the first quarter of 2022.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

| *Life science:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2022

| *Medical office:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2022

| *Life science:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2022

| Square feet | | | | | | 10,391 | | | | | | 426 | | | | | | 434 | | | | | | 1,185 | | | | | | 595 | | | | | | 1,502 | | | | | | 689 | | | | | | 851 | | | | | | 1,210 | | | | | | 1,434 | | | | | | 716 | | | | | | 1,349 | | |

Dropped from FY2022

| Base rent(2) | | | | | | $ | 577,446 | | | | | $ | 27,000 | | | | | $ | 29,065 | | | | | $ | 52,416 | | | | | $ | 25,919 | | | | | $ | 71,660 | | | | | $ | 36,699 | | | | | $ | 52,804 | | | | | $ | 80,566 | | | | | $ | 77,799 | | | | | $ | 46,268 | | | | | $ | 77,250 | |

Dropped from FY2022

| *Medical office:* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2022

| Square feet | | | | | | 21,486 | | | | | | 2,517 | | | | | | 2,383 | | | | | | 4,646 | | | | | | 1,791 | | | | | | 1,809 | | | | | | 1,920 | | | | | | 1,285 | | | | | | 1,150 | | | | | | 1,576 | | | | | | 1,348 | | | | | | 1,061 | | |

Dropped from FY2022

| Base rent(2) | | | | | | $ | 528,467 | | | | | $ | 68,969 | | | | | $ | 69,119 | | | | | $ | 93,238 | | | | | $ | 48,715 | | | | | $ | 47,585 | | | | | $ | 38,533 | | | | | $ | 33,233 | | | | | $ | 30,386 | | | | | $ | 37,707 | | | | | $ | 27,075 | | | | | $ | 33,907 | |

Dropped from FY2022

| Base rent(2) | | | | | | $ | 1,105,913 | | | | | $ | 95,969 | | | | | $ | 98,184 | | | | | $ | 145,654 | | | | | $ | 74,634 | | | | | $ | 119,245 | | | | | $ | 75,232 | | | | | $ | 86,037 | | | | | $ | 110,952 | | | | | $ | 115,506 | | | | | $ | 73,343 | | | | | $ | 111,157 | |

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Item 4. Mine Safety Disclosures

0 rewritten, 0 added, 1 removed, 2 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

27 rewritten, 6 added, 10 removed, 22 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

[removed: At January 27, 2023,] [added: As of February 5, 2024,] we had [removed: 7,206] [added: 6,797] stockholders of record, and there were [removed: 270,018] [added: 283,417] beneficial holders of our common stock.

Rewritten

| | | | [removed: 2022] [added: 2019] | | | | | | [added: 2020 | | | | | |] 2021 | | | | | | [removed: 2020] [added: 2022] | | | [added: | | | 2023 | | |]

Rewritten

| Ordinary dividends(1) | | | $ | [removed: 0.872948] [added: 0.909692] | | | | | $ | [removed: 0.152336] [added: 0.872948] | | | | | $ | [removed: 0.713864] [added: 0.152336] | |

Rewritten

| Capital gains(2)(3) | | | [removed: 0.183208] [added: 0.116992] | | | | | | [removed: 0.379960] [added: 0.183208] | | | | | | [removed: 0.529796] [added: 0.379960] | | |

Rewritten

| Nondividend distributions | | | [removed: 0.143844] [added: 0.173316] | | | | | | [removed: 0.667704] [added: 0.143844] | | | | | | [removed: 0.236340] [added: 0.667704] | | |

Rewritten

| | | | $ | 1.200000 | | | | | $ | 1.200000 | | | | | $ | [removed: 1.480000] [added: 1.200000] | |

Rewritten

[removed: (1)For] [added: For] the year ended December 31, 2022, all $0.872948 of ordinary dividends qualified as business income for purposes of Code Section 199A.

Rewritten

[removed: For] [added: (1)For] the year ended December 31, [removed: 2020, all $0.713864] [added: 2023, the amount includes $0.882312] of ordinary dividends qualified as business income for purposes of Code Section [removed: 199A.][added: 199A and $0.027380 of qualified dividend income for purposes of Code Section 1(h)(11).]

Rewritten

(2)For the years ended December 31, [added: 2023,] 2022, [removed: 2021,] and [removed: 2020,] [added: 2021,] the amount includes [added: $0.036256,] $0.017760, [removed: $0.379960,] and [removed: $0.221420,] [added: $0.379960,] respectively, of [removed: Unrecaptured] [added: unrecaptured Code] Section 1250 gain.

Rewritten

[removed: Code Section 1061 is generally applicable to direct and indirect holders of “applicable partnership interests.”] For the year ended December 31, 2022, the “One Year Amounts” and “Three Year Amounts” are [added: each] 89.6708% of the total capital gain distributions and the remaining capital gain distributions are attributable to Code Section 1231 gains, which are not subject to Code Section 1061.

Rewritten

For the [removed: years] [added: year] ended December 31, [removed: 2021 and 2020,] [added: 2021,] the “One Year Amounts” and “Three Year Amounts” are each zero, since all capital gains relate to Code Section 1231 gains.

Rewritten

(3)For the years ended December 31, [added: 2023,] 2022, [removed: 2021,] and [removed: 2020, 10.3292%,] [added: 2021,] 100%, [added: 10.3292%,] and 100%, respectively, of the capital gain distributions represent gains from dispositions of U.S. real property interests pursuant to Code Section 897 for foreign shareholders.

Rewritten

On [removed: February 1, 2023,] [added: January 31, 2024,] we announced that our Board of Directors declared a quarterly common stock cash dividend of $0.30 per share.

Rewritten

The common stock dividend will be paid on February [removed: 23, 2023] [added: 26, 2024] to stockholders of record as of the close of business on February [removed: 9, 2023.][added: 14, 2024.]

Rewritten

The following table sets forth information with respect to purchases of our common stock made by or on our behalf during the [removed: quarter] [added: three months] ended December 31, [removed: 2022.][added: 2023.]

Rewritten

| Period Covered | | | | | | Total Number of Shares [removed: Purchased(1)] [added: Purchased] | | | | | | Average Price Paid per Share | | | | | | Total Number of Shares Purchased as Part of Publicly Announced Plans or [removed: Programs(2)] [added: Programs(1)] | | | | | | Maximum Number (or Approximate Dollar Value) of Shares that May Yet be Purchased Under the Plans or [removed: Programs(2)] [added: Programs(1)] | | |

Rewritten

| October 1-31, [removed: 2022] [added: 2023] | | | | | | [removed: 4,853] [added: —] | | | | | | $ | [removed: 22.92] [added: —] | | | | | — | | | | | | $ | 444,018,701 | |

Rewritten

| November 1-30, [removed: 2022] [added: 2023] | | | | | | [removed: 3,256] [added: —] | | | | | | [removed: 24.01] [added: —] | | | | | | — | | | | | | 444,018,701 | | |

Rewritten

| December 1-31, [removed: 2022] [added: 2023] | | | | | | [removed: 244] [added: —] | | | | | | [removed: 25.49] [added: —] | | | | | | — | | | | | | 444,018,701 | | |

Rewritten

| | | | | | | [removed: 8,353] [added: —] | | | | | | $ | [removed: 23.42] [added: —] | | | | | — | | | | | | $ | 444,018,701 | |

Rewritten

[removed: (2)On] [added: (1)On] August 1, 2022, our Board of Directors approved a share repurchase program under which we may acquire shares of our common stock in the open market up to an aggregate purchase price of $500 million (the “Share Repurchase Program”).

Rewritten

[removed: In August] [added: During the year ended December 31,] 2022, we repurchased 2.1 million shares of our common stock at a weighted average price of $27.16 per share.

Rewritten

During the [removed: fourth quarter of 2022,] [added: year ended December 31, 2023,] there were no repurchases; therefore, at December 31, [removed: 2022,] [added: 2023,] $444 million of our common stock remained available for repurchase under the Share Repurchase Program.

Rewritten

The graph and table below compare the cumulative total return of Healthpeak, the S&P 500 Index, and the Equity REIT Index of Nareit, from January 1, [removed: 2018] [added: 2019] to December 31, [removed: 2022.][added: 2023.]

Rewritten

Total cumulative return is based on a $100 investment in Healthpeak common stock and in each of the indices at the close of trading on December [removed: 29, 2017] [added: 31, 2018] and assumes quarterly reinvestment of dividends before consideration of income taxes.

Rewritten

(JANUARY 1, [removed: 2018] [added: 2019] = $100)

Rewritten

[removed: ![peak-20221231_g1.jpg](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/peak-20221231_g1.jpg)][added: ![5043](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/peak-20231231_g1.jpg)]

New in FY2023

| | | | 2023 | | | | | | 2022 | | | | | | 2021 | | |

New in FY2023

Code Section 1061 is generally applicable to direct and indirect holders of “applicable partnership interests.” For the year ended December 31, 2023, the “One Year Amounts” and “Three Year Amounts” are each zero, since all capital gains relate to Code Section 1231 gains.

New in FY2023

JANUARY 1, 2019–DECEMBER 31, 2023

New in FY2023

| FTSE Nareit Equity REIT Index | | | $ | 128.66 | | | | | $ | 122.07 | | | | | $ | 172.49 | | | | | $ | 129.45 | | | | | $ | 144.16 | |

New in FY2023

| S&P 500 | | | 131.47 | | | | | | 155.65 | | | | | | 200.29 | | | | | | 163.98 | | | | | | 207.04 | | |

New in FY2023

| Healthpeak Properties, Inc. | | | 129.11 | | | | | | 119.21 | | | | | | 147.52 | | | | | | 106.94 | | | | | | 89.40 | | |

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

(1)Represents shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations that occur upon vesting of restricted stock units.

Dropped from FY2022

The value of the shares withheld is based on the closing price of our common stock on the last trading day prior to the date the relevant transaction occurred.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

JANUARY 1, 2018–DECEMBER 31, 2022

Dropped from FY2022

| | | | 2018 | | | | | | 2019 | | | | | | 2020 | | | | | | 2021 | | | | | | 2022 | | |

Dropped from FY2022

| FTSE Nareit Equity REIT Index | | | $ | 95.96 | | | | | $ | 123.46 | | | | | $ | 117.14 | | | | | $ | 165.51 | | | | | $ | 124.22 | |

Dropped from FY2022

| S&P 500 | | | 95.61 | | | | | | 125.70 | | | | | | 148.81 | | | | | | 191.48 | | | | | | 156.77 | | |

Dropped from FY2022

| Healthpeak Properties, Inc. | | | 113.68 | | | | | | 146.78 | | | | | | 135.52 | | | | | | 167.70 | | | | | | 121.58 | | |

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Item 8. Financial Statements and Supplementary Data

1,125 rewritten, 368 added, 466 removed, 848 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | | | [removed: [59](#i0e89d5fc23c841beba74211ca606ff6b_100)] [added: [70](#i39cdee5f0c374353affc19f158b4853c_100)] | | |

Rewritten

| [Consolidated Balance [removed: Sheets—](#i0e89d5fc23c841beba74211ca606ff6b_103)December] [added: Sheets—](#i39cdee5f0c374353affc19f158b4853c_103)December] 31, [added: 2023 [and](#i39cdee5f0c374353affc19f158b4853c_103)] 2022 [removed: [and](#i0e89d5fc23c841beba74211ca606ff6b_103) 2021] | | | [removed: [61](#i0e89d5fc23c841beba74211ca606ff6b_103)] [added: [72](#i39cdee5f0c374353affc19f158b4853c_103)] | | |

Rewritten

| [Consolidated Statements of Operations—for the years [removed: ended](#i0e89d5fc23c841beba74211ca606ff6b_106)] [added: ended](#i39cdee5f0c374353affc19f158b4853c_106)] December 31, [removed: 2022[,](#i0e89d5fc23c841beba74211ca606ff6b_106) 2021[, and](#i0e89d5fc23c841beba74211ca606ff6b_106) 2020] [added: 2023[,](#i39cdee5f0c374353affc19f158b4853c_106) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_106) 2021] | | | [removed: [62](#i0e89d5fc23c841beba74211ca606ff6b_106)] [added: [73](#i39cdee5f0c374353affc19f158b4853c_106)] | | |

Rewritten

| [Consolidated Statements of Comprehensive Income (Loss)—for the years [removed: ended](#i0e89d5fc23c841beba74211ca606ff6b_109)] [added: ended](#i39cdee5f0c374353affc19f158b4853c_109)] December 31, [removed: 2022[,](#i0e89d5fc23c841beba74211ca606ff6b_109) 2021[, and](#i0e89d5fc23c841beba74211ca606ff6b_109) 2020] [added: 2023[,](#i39cdee5f0c374353affc19f158b4853c_109) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_109) 2021] | | | [removed: [63](#i0e89d5fc23c841beba74211ca606ff6b_109)] [added: [74](#i39cdee5f0c374353affc19f158b4853c_109)] | | |

Rewritten

| [Consolidated Statements of Equity and Redeemable Noncontrolling Interests—for the years [removed: ended](#i0e89d5fc23c841beba74211ca606ff6b_112)] [added: ended](#i39cdee5f0c374353affc19f158b4853c_112)] December 31, [removed: 2022[,](#i0e89d5fc23c841beba74211ca606ff6b_112) 2021[, and](#i0e89d5fc23c841beba74211ca606ff6b_112) 2020] [added: 2023[,](#i39cdee5f0c374353affc19f158b4853c_112) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_112) 2021] | | | [removed: [64](#i0e89d5fc23c841beba74211ca606ff6b_112)] [added: [75](#i39cdee5f0c374353affc19f158b4853c_112)] | | |

Rewritten

| [Consolidated Statements of Cash Flows—for the years [removed: ended](#i0e89d5fc23c841beba74211ca606ff6b_115)] [added: ended](#i39cdee5f0c374353affc19f158b4853c_115)] December 31, [removed: 2022[,](#i0e89d5fc23c841beba74211ca606ff6b_115) 2021[, and](#i0e89d5fc23c841beba74211ca606ff6b_115) 2020] [added: 2023[,](#i39cdee5f0c374353affc19f158b4853c_115) 2022[, and](#i39cdee5f0c374353affc19f158b4853c_115) 2021] | | | [removed: [66](#i0e89d5fc23c841beba74211ca606ff6b_115)] [added: [77](#i39cdee5f0c374353affc19f158b4853c_115)] | | |

Rewritten

| [Notes to the Consolidated Financial [removed: Statements](#i0e89d5fc23c841beba74211ca606ff6b_118)] [added: Statements](#i39cdee5f0c374353affc19f158b4853c_118)] | | | [removed: [67](#i0e89d5fc23c841beba74211ca606ff6b_118)] [added: [78](#i39cdee5f0c374353affc19f158b4853c_118)] | | |

Rewritten

We have audited the accompanying Consolidated Balance Sheets of Healthpeak Properties, Inc. and subsidiaries (the “Company”) as of December 31, [removed: 2022] [added: 2023] and [removed: 2021,] [added: 2022,] the related Consolidated Statements of Operations, Comprehensive Income (Loss), Equity and Redeemable Noncontrolling Interests, and Cash Flows, for each of the three years in the period ended December 31, [removed: 2022,] [added: 2023,] and the related Notes and the schedules listed in the Index at Item 15 (collectively referred to as the “financial statements”).

Rewritten

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, [removed: 2022] [added: 2023] and [removed: 2021,] [added: 2022,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2022,] [added: 2023,] in conformity with accounting principles generally accepted in the United States of America.

Rewritten

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2022,] [added: 2023,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February [removed: 8, 2023,] [added: 9, 2024,] expressed an unqualified opinion on the Company’s internal control over financial reporting.

Rewritten

Impairments — Real Estate — Refer to Notes 2 and [removed: 6] [added: 5] to the financial statements

Rewritten

Given the Company’s evaluation of impairment indicators, forecasted cash flows and sales prices of a [removed: long lived] [added: long-lived] asset requires management to make significant estimates and assumptions related to market capitalization rates, market prices per unit, and/or forecasted cash flows, performing audit procedures required a high degree of auditor judgment and an increased extent of effort.

Rewritten

- We tested the effectiveness of controls over impairment of real estate assets, including those over identifying impairment [removed: indicators,] [added: indicators] and the determination of forecasted undiscounted cash flows and sales prices for real estate assets.

Rewritten

| | | | [added: 2023 | | | | | |] 2022 | | | | | | 2021 | | |

Rewritten

| Buildings and improvements | | | $ | [removed: 12,784,078] [added: 13,329,464] | | | | | $ | [removed: 12,025,271] [added: 12,784,078] | |

Rewritten

| Development costs and construction in progress | | | [removed: 760,355] [added: 643,217] | | | | | | [removed: 877,423] [added: 760,355] | | |

Rewritten

| Accumulated depreciation and amortization | | | [removed: (3,188,138)] [added: (3,591,951)] | | | | | | [removed: (2,839,229)] [added: (3,188,138)] | | |

Rewritten

| Net real estate | | | [removed: 13,023,483] [added: 13,028,363] | | | | | | [removed: 12,667,429] [added: 13,023,483] | | |

Rewritten

| Loans receivable, net of reserves of [removed: $8,280] [added: $2,830] and [removed: $1,813] [added: $8,280] | | | [removed: 374,832] [added: 218,450] | | | | | | [removed: 415,811] [added: 374,832] | | |

Rewritten

| Investments in and advances to unconsolidated joint ventures | | | [removed: 706,677] [added: 782,853] | | | | | | [removed: 403,634] [added: 706,677] | | |

Rewritten

| Accounts receivable, net of allowance of [removed: $2,399] [added: $2,282] and [removed: $1,870] [added: $2,399] | | | [removed: 53,436] [added: 55,820] | | | | | | [removed: 48,691] [added: 53,436] | | |

Rewritten

| Cash and cash equivalents | | | [added: | | | $ | 117,635 | | | | | $ |] 72,032 | | | | | [added: $] | 158,287 | | | [added: | | $ | — | | | | | $ | — | | | | | $ | 7,707 | | | | | $ | 117,635 | | | | | $ | 72,032 | | | | | $ | 165,994 | |]

Rewritten

| Restricted cash | | | [added: | | | 51,388 | | | | | |] 54,802 | | | | | | 53,454 | | | [added: | | | — | | | | | | — | | | | | | — | | | | | | 51,388 | | | | | | 54,802 | | | | | | 53,454 | | |]

Rewritten

| Intangible assets, net | | | [removed: 418,061] [added: 314,156] | | | | | | [removed: 519,760] [added: 418,061] | | |

Rewritten

| Assets held for [removed: sale and discontinued operations,] [added: sale,] net | | | [removed: 49,866] [added: 117,986] | | | | | | [removed: 37,190] [added: 49,866] | | |

Rewritten

| Right-of-use asset, net | | | [removed: 237,318] [added: 240,155] | | | | | | [removed: 233,942] [added: 237,318] | | |

Rewritten

| Other assets, net | | | [removed: 780,722] [added: 772,044] | | | | | | [removed: 674,615] [added: 780,722] | | |

Rewritten

| Total assets | | | $ | [removed: 15,771,229] [added: 15,698,850] | | | | | $ | [removed: 15,257,519] [added: 15,771,229] | |

Rewritten

| Bank line of credit and commercial paper | | | $ | [removed: 995,606] [added: 720,000] | | | | | $ | [removed: 1,165,975] [added: 995,606] | |

Rewritten

| Term loans | | | [removed: 495,957] [added: 496,824] | | | | | | [removed: —] [added: 495,957] | | |

Rewritten

| Senior unsecured notes | | | [removed: 4,659,451] [added: 5,403,378] | | | | | | [removed: 4,651,933] [added: 4,659,451] | | |

Rewritten

| Mortgage debt | | | [removed: 346,599] [added: 256,097] | | | | | | [removed: 352,081] [added: 346,599] | | |

Rewritten

| Intangible liabilities, net | | | [removed: 156,193] [added: 127,380] | | | | | | [removed: 177,232] [added: 156,193] | | |

Rewritten

| Liabilities related to assets held for [removed: sale and discontinued operations,] [added: sale,] net | | | [removed: 4,070] [added: 729] | | | | | | [removed: 15,056] [added: 4,070] | | |

Rewritten

| Lease liability | | | [removed: 208,515] [added: 206,743] | | | | | | [removed: 204,547] [added: 208,515] | | |

Rewritten

| Accounts payable, accrued liabilities, and other liabilities | | | [removed: 772,485] [added: 657,196] | | | | | | [removed: 755,384] [added: 772,485] | | |

Rewritten

| Deferred revenue | | | [removed: 844,076] [added: 905,633] | | | | | | [removed: 789,207] [added: 844,076] | | |

Rewritten

| Total liabilities | | | [removed: 8,482,952] [added: 8,773,980] | | | | | | [removed: 8,111,415] [added: 8,482,952] | | |

Rewritten

| Commitments and contingencies (Note [removed: 12)] [added: 11)] | | | | | | | | | | | |

Rewritten

| Redeemable noncontrolling interests | | | [removed: 105,679] [added: 48,828] | | | | | | [removed: 87,344] [added: 105,679] | | |

New in FY2023

February 9, 2024

New in FY2023

| Land and improvements | | | 2,647,633 | | | | | | 2,667,188 | | |

New in FY2023

| Restricted cash | | | 51,388 | | | | | | 54,802 | | |

New in FY2023

| December 31, 2022 | | | 546,642 | | | | | | $ | 546,642 | | | | | $ | 10,349,614 | | | | | $ | (4,269,689) | | | | | $ | 28,134 | | | | | $ | 6,654,701 | | | | | $ | 527,897 | | | | | $ | 7,182,598 | | | | | $ | 105,679 | |

New in FY2023

| Net income (loss) | | | — | | | | | | — | | | | | | — | | | | | | 306,009 | | | | | | — | | | | | | 306,009 | | | | | | 28,111 | | | | | | 334,120 | | | | | | 637 | | |

New in FY2023

| Issuance of common stock, net | | | 683 | | | | | | 683 | | | | | | 755 | | | | | | — | | | | | | — | | | | | | 1,438 | | | | | | — | | | | | | 1,438 | | | | | | — | | |

New in FY2023

| Repurchase of common stock | | | (241) | | | | | | (241) | | | | | | (6,283) | | | | | | — | | | | | | — | | | | | | (6,524) | | | | | | — | | | | | | (6,524) | | | | | | — | | |

New in FY2023

| December 31, 2023 | | | 547,156 | | | | | | $ | 547,156 | | | | | $ | 10,405,780 | | | | | $ | (4,621,861) | | | | | $ | 19,371 | | | | | $ | 6,350,446 | | | | | $ | 525,596 | | | | | $ | 6,876,042 | | | | | $ | 48,828 | |

New in FY2023

On February 10, 2023, the Company completed its corporate reorganization (the “Reorganization”) into an umbrella partnership REIT (“UPREIT”).

New in FY2023

Substantially all of the Company’s business is conducted through Healthpeak OP, LLC (“Healthpeak OP”).

New in FY2023

The Company is the managing member of Healthpeak OP and does not have material assets or liabilities, other than through its investment in Healthpeak OP.

New in FY2023

For additional information on the UPREIT reorganization, see the Company’s Current Report on Form 8-K12B filed with the U.S. Securities and Exchange Commission (“SEC”) on February 10, 2023.

New in FY2023

*The Merger Agreement*

New in FY2023

On October 29, 2023, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Physicians Realty Trust, Physicians Realty L.P. (the “Physicians Partnership”), and certain of the Company’s subsidiaries, pursuant to which, among other things, and through a series of transactions (the “Mergers”), (i) each outstanding common share of Physicians Realty Trust (other than Physicians Realty Trust common shares to be canceled in accordance with the Merger Agreement) will be converted into the right to receive 0.674 (the “Exchange Ratio”) shares of Company common stock, and (ii) each outstanding common unit of the Physicians Partnership will be converted into common units in the successor entity to the Physicians Partnership equal to the Exchange Ratio.

New in FY2023

Following the transactions contemplated in the Merger Agreement, the successor entities to Physicians Realty Trust and the Physicians Partnership will be subsidiaries of Healthpeak OP.

New in FY2023

The Merger Agreement contains customary representations, warranties, and covenants, as well as certain termination rights for the Company and Physicians Realty Trust, in each case, as more fully described in the Merger Agreement.

New in FY2023

During the year ended December 31, 2023, the Company incurred approximately $11 million of merger-related costs, which primarily related to advisory, legal, accounting, and other costs.

New in FY2023

In addition, the Company has engaged service providers, including investment banks and advisors, to help the Company negotiate the terms of the transactions contemplated by the Merger Agreement and to advise the Company on other merger-related matters.

New in FY2023

In connection with these services, the Company expects to be required to pay success-based fees to the extent that certain conditions, including the closing of the transactions contemplated by the Merger Agreement, are met.

New in FY2023

As of December 31, 2023, the Company expects to incur approximately $22 million of such success fees.

New in FY2023

As closing of the transactions contemplated by the Merger Agreement has not occurred, no such amounts have been paid or accrued through December 31, 2023.

New in FY2023

In connection with the Mergers, the Company filed a Registration Statement on Form S-4 with the SEC on December 15, 2023 (the “Initial Filing”), as amended on January 9, 2024, and a definitive joint proxy statement/prospectus for the Company and Physicians Realty Trust on January 11, 2024 in connection with their respective special meetings of stockholders and shareholders, as applicable, which will be held on February 21, 2024.

New in FY2023

Consummation of the Mergers are subject to the satisfaction or waiver of customary closing conditions, including the approval of the Company’s stockholders and the shareholders of Physicians Realty Trust.

New in FY2023

The parties expect the Mergers to close on March 1, 2024.

New in FY2023

If the Mergers are not consummated by July 31, 2024 (unless extended under certain circumstances), either the Company or Physicians Realty Trust may terminate the Merger Agreement.

New in FY2023

The Company does not resume recognition of income on a straight-line basis unless it determines that collectibility of future payments related to these leases is probable.

New in FY2023

For the Company’s portfolio of operating leases that are deemed probable of collection but exhibit a certain level of collectibility risk, the Company may also recognize an incremental allowance as a reduction to revenue.

New in FY2023

These useful lives are reassessed following changes in the remaining period that the asset is expected to be held and used, and depreciation is discontinued when a property meets the criteria to be classified as held for sale.

New in FY2023

*Healthpeak OP*

New in FY2023

Immediately following the Reorganization, Healthpeak Properties, Inc. was the initial sole member and 100% owner of Healthpeak OP.

New in FY2023

Subsequent to the Reorganization, certain employees of the Company (“OP Unitholders”) were issued noncontrolling, non-managing member units in Healthpeak OP (“OP Units”).

New in FY2023

When certain conditions are met, the OP Unitholders have the right to require redemption of part or all of their OP Units for cash or shares of the Company’s common stock, at the Company’s option as managing member of Healthpeak OP.

New in FY2023

The per unit redemption amount is equal to either one share of the Company’s common stock or cash equal to the fair value of a share of common stock at the time of redemption.

New in FY2023

The Company classifies the OP Units in permanent equity because it may elect, in its sole discretion, to issue shares of its common stock to OP Unitholders who choose to redeem their OP Units rather than using cash.

New in FY2023

*DownREITs*

New in FY2023

*Adopted*

New in FY2023

During the first quarter of 2023, the Company amended certain of its variable rate mortgage debt and the related interest rate swap agreements to change the interest rate benchmark from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) and accordingly, the Company elected to apply certain practical expedients provided by these ASUs related to cash flow hedges.

New in FY2023

*Not Yet Adopted*

New in FY2023

*Segment Reporting.* In November 2023, the FASB issued ASU No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures* (“ASU 2023-07”), to improve reportable segment disclosure requirements so that investors can better understand an entity’s overall performance and assess potential future cash flows.

New in FY2023

The amendments in ASU 2023-07 include, but are not limited to: (i) disclosure of, on an annual basis, significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss; (ii) disclosure of, on an annual and interim basis, an amount for other segment items by reportable segment and a description of its composition (the other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss); (iii) disclosure of, on an interim basis, all currently required annual disclosures about a reportable segment’s profit (loss) and assets; (iv) clarification that if the CODM uses more than one measure of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources, an entity may report one or more of those additional measures of segment profit; and (v) disclosure of the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

February 8, 2023

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

| | | | December 31, | | | | | | | | |

Dropped from FY2022

| ASSETS | | | | | | | | | | | |

Dropped from FY2022

| Land | | | 2,667,188 | | | | | | 2,603,964 | | |

Dropped from FY2022

| Net investment in direct financing leases | | | — | | | | | | 44,706 | | |

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

[Table](#i0e89d5fc23c841beba74211ca606ff6b_7) [of](#i0e89d5fc23c841beba74211ca606ff6b_7) [Contents](#i0e89d5fc23c841beba74211ca606ff6b_7)

Dropped from FY2022

| December 31, 2019 | | | 505,222 | | | | | | $ | 505,222 | | | | | $ | 9,175,277 | | | | | $ | (3,601,199) | | | | | $ | (2,857) | | | | | $ | 6,076,443 | | | | | $ | 582,416 | | | | | $ | 6,658,859 | | | | | $ | 11,106 | |

Dropped from FY2022

| Impact of adoption of ASU No. 2016-13(1) | | | — | | | | | | — | | | | | | — | | | | | | (1,524) | | | | | | — | | | | | | (1,524) | | | | | | — | | | | | | (1,524) | | | | | | — | | |

Dropped from FY2022

| January 1, 2020 | | | 505,222 | | | | | | $ | 505,222 | | | | | $ | 9,175,277 | | | | | $ | (3,602,723) | | | | | $ | (2,857) | | | | | $ | 6,074,919 | | | | | $ | 582,416 | | | | | $ | 6,657,335 | | | | | $ | 11,106 | |

Dropped from FY2022

| Net income (loss) | | | — | | | | | | — | | | | | | — | | | | | | 413,563 | | | | | | — | | | | | | 413,563 | | | | | | 14,690 | | | | | | 428,253 | | | | | | — | | |

Dropped from FY2022

| Issuance of common stock, net | | | 33,307 | | | | | | 33,307 | | | | | | 1,033,764 | | | | | | — | | | | | | — | | | | | | 1,067,071 | | | | | | — | | | | | | 1,067,071 | | | | | | — | | |

Dropped from FY2022

| Repurchase of common stock | | | (298) | | | | | | (298) | | | | | | (10,231) | | | | | | — | | | | | | — | | | | | | (10,529) | | | | | | — | | | | | | (10,529) | | | | | | — | | |

Dropped from FY2022

| December 31, 2021 | | | 539,097 | | | | | | $ | 539,097 | | | | | $ | 10,100,294 | | | | | $ | (4,120,774) | | | | | $ | (3,147) | | | | | $ | 6,515,470 | | | | | $ | 543,290 | | | | | $ | 7,058,760 | | | | | $ | 87,344 | |

Dropped from FY2022

(1)On January 1, 2020, the Company adopted a series of Accounting Standards Updates (“ASUs”) related to accounting for credit losses and recognized the cumulative-effect of adoption to beginning retained earnings.

Dropped from FY2022

Refer to Note 2 for a detailed impact of adoption.

Dropped from FY2022

| Acquisition of CCRC Portfolio | | | — | | | | | | — | | | | | | (394,177) | | | | | |

Dropped from FY2022

| Effect of foreign exchanges on cash, cash equivalents and restricted cash | | | — | | | | | | — | | | | | | (153) | | | | | |

Dropped from FY2022

On February 7, 2023, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with New Healthpeak, Inc., a Maryland corporation (“New Healthpeak”) and its wholly owned subsidiary, and Healthpeak Merger Sub, Inc., a Maryland corporation (“Merger Sub”) that is a wholly owned subsidiary of New Healthpeak.

Dropped from FY2022

The purpose of the transactions contemplated by the Merger Agreement is for the Company to implement a corporate reorganization into a new holding company structure commonly referred to as an Umbrella Partnership Real Estate Investment Trust, or UPREIT (the “Reorganization”).

Dropped from FY2022

Pursuant to the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of New Healthpeak (the “Merger”).

Dropped from FY2022

The Merger is expected to be effective as of February 10, 2023 (the “Effective Time”).

Dropped from FY2022

As part of the Merger, the Company’s name will change to Healthpeak Properties Interim, Inc., and, effective immediately after the Effective Time, New Healthpeak’s name will be changed to Healthpeak Properties, Inc. The Merger is expected to be conducted in accordance with Section 3-106.2 of the Maryland General Corporation Law.

Dropped from FY2022

Accordingly, the Merger will not require the approval of the Company’s stockholders, and the Merger will not give rise to statutory dissenters’ rights.

Dropped from FY2022

In connection with the Reorganization and immediately following the Merger, the Company will convert from a Maryland corporation to a Maryland limited liability company named Healthpeak OP, LLC (“Healthpeak OP”).

Dropped from FY2022

Following the Merger, the business, management and board of directors of New Healthpeak will be identical to the business, management and board of directors of the company immediately before the Merger, except that the business of the company is expected to be conducted exclusively through Healthpeak OP.

Dropped from FY2022

The consolidated assets and liabilities of New Healthpeak immediately following the Merger will be identical to the consolidated assets and liabilities of the Company immediately prior to the Merger.

Dropped from FY2022

New Healthpeak will not hold any assets directly other than its ownership interest in Healthpeak OP and certain de minimis assets that may be held for certain administrative functions.

Dropped from FY2022

None of the properties owned by the Company or its subsidiaries or any interests therein will be transferred as part of the Reorganization.

Dropped from FY2022

All material indebtedness of the Company immediately prior to the Merger will remain the indebtedness of Healthpeak OP after the Merger.

Dropped from FY2022

If it is no longer probable that substantially all future minimum lease payments under operating leases will be received, the accounts receivable and straight-line rent receivable balance is written off and recognized as a decrease in revenue in that period.

Dropped from FY2022

Depreciation is discontinued when a property is identified as held for sale.

Dropped from FY2022

Foreign Currency Translation and Transactions

Dropped from FY2022

Assets and liabilities denominated in foreign currencies that are translated into U.S. dollars use exchange rates in effect at the end of the period, and revenues and expenses denominated in foreign currencies that are translated into U.S. dollars use average rates of exchange in effect during the related period.

Dropped from FY2022

Gains or losses resulting from translation are included in accumulated other comprehensive income (loss).

Dropped from FY2022

Gains or losses resulting from foreign currency transactions are translated into U.S. dollars at the rates of exchange prevailing at the dates of the transactions.

Dropped from FY2022

The effects of transaction gains or losses are included in other income (expense), net in the Consolidated Statements of Operations.

An excerpt. Shown here: 40 of 1,125 rewritten, 40 of 368 added and 40 of 466 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2023 filing and the FY2022 filing.

Item 9A. Controls and Procedures

8 rewritten, 1 added, 1 removed, 22 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, [removed: 2022.][added: 2023.]

Rewritten

Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, [removed: 2022.][added: 2023.]

Rewritten

Based on our evaluation under the framework in *Internal Control—Integrated Framework (2013)*, our management concluded that our internal control over financial reporting was effective as of December 31, [removed: 2022.][added: 2023.]

Rewritten

The effectiveness of our internal control over financial reporting as of December 31, [removed: 2022] [added: 2023] has been audited by Deloitte & Touche LLP, the independent registered public accounting firm that audited the financial statements included in this Annual Report on Form 10-K, as stated in their report, which is included herein.

Rewritten

*Changes in Internal Control Over Financial Reporting.* There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of [removed: 2022] [added: 2023] that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Rewritten

We have audited the internal control over financial reporting of Healthpeak Properties, Inc. and subsidiaries (the “Company”) as of December 31, [removed: 2022,] [added: 2023,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Rewritten

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2022,] [added: 2023,] based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

Rewritten

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, [removed: 2022,] [added: 2023,] of the Company and our report dated February [removed: 8, 2023,] [added: 9, 2024,] expressed an unqualified opinion on those financial statements.

New in FY2023

February 9, 2024

Dropped from FY2022

February 8, 2023

Item 9B. Other Information

0 rewritten, 2 added, 1 removed, 0 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

New in FY2023

Insider Trading Arrangements

New in FY2023

During the three months ended December 31, 2023, none of our directors or Section 16 officers adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement.

Dropped from FY2022

None.

Item 10. Directors, Executive Officers and Corporate Governance

1 rewritten, 0 added, 0 removed, 4 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

Except as provided below, the information required under Item 10 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2022] [added: 2023] in connection with our [removed: 2023] [added: 2024] Annual Meeting of Stockholders.

Item 11. Executive Compensation

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

The information required under Item 11 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2022] [added: 2023] in connection with our [removed: 2023] [added: 2024] Annual Meeting of Stockholders.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

The information required under Item 12 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2022] [added: 2023] in connection with our [removed: 2023] [added: 2024] Annual Meeting of Stockholders.

Item 13. Certain Relationships and Related Transactions, and Director Independence

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

The information required under Item 13 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2022] [added: 2023] in connection with our [removed: 2023] [added: 2024] Annual Meeting of Stockholders.

Item 14. Principal Accountant Fees and Services

1 rewritten, 0 added, 0 removed, 1 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

The information required under Item 14 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, [removed: 2022] [added: 2023] in connection with our [removed: 2023] [added: 2024] Annual Meeting of Stockholders.

Item 15. Exhibits and Financial Statement Schedules

33 rewritten, 19 added, 24 removed, 47 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

Report of Independent Registered Public Accounting Firm [added: (PCAOB ID No. 34)]

Rewritten

Consolidated Balance Sheets - December 31, [removed: 2022] [added: 2023] and [removed: 2021][added: 2022]

Rewritten

Consolidated Statements of Operations - for the years ended December 31, [added: 2023,] 2022, [removed: 2021,] and [removed: 2020][added: 2021]

Rewritten

Consolidated Statements of Comprehensive Income (Loss) - for the years ended December 31, [added: 2023,] 2022, [removed: 2021,] and [removed: 2020][added: 2021]

Rewritten

Consolidated Statements of Equity and Redeemable Noncontrolling Interests - for the years ended December 31, [added: 2023,] 2022, [removed: 2021,] and [removed: 2020][added: 2021]

Rewritten

Consolidated Statements of Cash Flows - for the years ended December 31, [added: 2023,] 2022, [removed: 2021,] and [removed: 2020][added: 2021]

Rewritten

| [removed: 3.1] [added: 10.10*] | | | | | | [removed: [Articles of Restatement of] [added: [Amended and Restated] Healthpeak Properties, Inc. [removed: (formerly HCP, Inc.) dated June 1, 2012, as supplemented by the Articles Supplementary, dated July 31, 2017, and] [added: 2014 Performance Incentive Plan,] as amended [removed: by the Articles of Amendment, dated] [added: through] October [removed: 30, 2019.](http://www.sec.gov/Archives/edgar/data/765880/000162828020001456/ex3112312019.htm)] [added: 24, 2019.](http://www.sec.gov/Archives/edgar/data/765880/000162828020001456/ex10612312019.htm)] | | | | | | Annual Report on Form 10-K | | | | | | February 13, 2020 | | |

Rewritten

| [removed: 3.2] [added: 3.3] | | | | | | [removed: [Sixth Amended] [added: [Amended] and Restated Bylaws of [removed: Healthpeak,] [added: Healthpeak] Properties, [removed: Inc.,] [added: Inc. (formerly New Healthpeak, Inc.),] dated [removed: October 30, 2019.](http://www.sec.gov/Archives/edgar/data/765880/000076588019000006/exh32sixtharbylaws.htm)] [added: February 10, 2023](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-4.htm)] | | | | | | Current Report on Form [removed: 8-K] [added: 8-K12B] | | | | | | [removed: October 30, 2019] [added: February 10, 2023] | | |

Rewritten

| [removed: 4.2] [added: 4.1.2] | | | | | | [removed: [Indenture,] [added: [Second Supplemental Indenture,] dated [removed: November 21, 2012,] [added: as of February 10, 2023,] between Healthpeak [added: OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor,] and The Bank of New York Mellon Trust Company, N.A., as [removed: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465912078913/a12-23861_7ex4d1.htm)] [added: trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex4-1.htm)] | | | | | | Current Report on Form [removed: 8‑K] [added: 8-K12B] | | | | | | [removed: November 19, 2012] [added: February 10, 2023] | | |

Rewritten

| [removed: 4.13] [added: 4.14†] | | | | | | [Description of Healthpeak Capital [removed: Stock.](http://www.sec.gov/Archives/edgar/data/765880/000162828020001456/ex41512312019.htm)] [added: Stock.](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex41412312023.htm)] | | | | | | [removed: Annual Report on Form 10-K] | | | | | | [removed: February 13, 2020] | | |

Rewritten

| [removed: 10.1] [added: 10.3] | | | | | | [Second Amended and Restated Credit Agreement, dated as of September 20, 2021, by and among Healthpeak, as borrower, the lenders referred to therein, and Bank of America, N.A., as administrative agent.](http://www.sec.gov/Archives/edgar/data/765880/000110465921117350/tm2127869d1_ex10-1.htm) | | | | | | Current Report on Form 8-K | | | | | | September 20, 2021 | | |

Rewritten

| [removed: 10.2] [added: 10.4] | | | | | | [Term Loan Agreement, dated as of August 22, 2022, by and among Healthpeak, as borrower, the lenders referred to therein, and Bank of America, N.A., as administrative agent.](http://www.sec.gov/Archives/edgar/data/765880/000110465922093367/tm2224182d1_ex10-1.htm) | | | | | | Current Report on Form 8-K | | | | | | August 22, 2022 | | |

Rewritten

| [removed: 10.3] [added: 10.5] | | | | | | [At-the-Market Equity Offering Sales Agreement, dated [removed: February 19, 2020, among] [added: February](http://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm) [17, 2023,](http://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm) [among Healthpeak](http://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm) [Properties, Inc.,] Healthpeak [removed: and] [added: OP, LLC,](http://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm) [and] the sales agents, forward sellers and forward purchasers referred to [removed: therein.](http://www.sec.gov/Archives/edgar/data/765880/000110465920022900/tm208255d3_ex1-1.htm)] [added: therein.](http://www.sec.gov/Archives/edgar/data/765880/000110465923023082/tm235984d32_ex1-1.htm)] | | | | | | Current Report on Form 8-K | | | | | | February [removed: 19, 2020] [added: 17, 2023] | | |

Rewritten

| [removed: 10.4*] [added: 10.6*] | | | | | | [Second Amended and Restated Director Deferred Compensation Plan.](http://www.sec.gov/Archives/edgar/data/765880/000110465909062019/a09-30798_1ex10d2.htm) | | | | | | Quarterly Report on Form 10‑Q | | | | | | November 3, 2009 | | |

Rewritten

| [removed: 10.5*] [added: 10.7*] | | | | | | [Non-Employee Directors Stock-for-Fees Program.](http://www.sec.gov/Archives/edgar/data/765880/000110465914056632/a14-13936_1ex10d11.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | August 5, 2014 | | |

Rewritten

| [removed: 10.6*] [added: 10.8*] | | | | | | [Executive Severance [removed: Plan.](http://www.sec.gov/Archives/edgar/data/765880/000155837016008927/hcp-20160930ex103b37731.htm)] [added: Plan (as amended and restated as of April 27, 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101503312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: November 1, 2016] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.7*] [added: 10.9*] | | | | | | [Executive Change in Control Severance Plan (as amended and restated as of [removed: May 6, 2016).](http://www.sec.gov/Archives/edgar/data/765880/000155837016008927/hcp-20160930ex104feff3a.htm)] [added: April 27, 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101603312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: November 1, 2016] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11*] [added: 10.10.1*] | | | | | | [removed: [Amended] [added: [First Amendment to Amended] and Restated Healthpeak Properties, Inc. 2014 Performance Incentive [removed: Plan, as amended through October 24, 2019.](http://www.sec.gov/Archives/edgar/data/765880/000162828020001456/ex10612312019.htm)] [added: Plan.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-5.htm)] | | | | | | [removed: Annual] [added: Current] Report on Form [removed: 10-K] [added: 8-K12B] | | | | | | February [removed: 13, 2020] [added: 10, 2023] | | |

Rewritten

| [removed: 10.11.1*] [added: 10.10.2*] | | | | | | [Form of 2014 Performance Incentive Plan Non-NEO Restricted Stock Unit Award Agreement (adopted 2014).](http://www.sec.gov/Archives/edgar/data/765880/000110465914056632/a14-13936_1ex10d9.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | August 5, 2014 | | |

Rewritten

| [removed: 10.11.2*] [added: 10.10.6*] | | | | | | [Form of 2014 Performance Incentive Plan [removed: Non-NEO Option] [added: NEO Retentive LTIP Unit] Agreement (adopted [removed: 2014).](http://www.sec.gov/Archives/edgar/data/765880/000110465914056632/a14-13936_1ex10d10.htm)] [added: 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10703312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: August 5, 2014] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11.3*] [added: 10.10.3*] | | | | | | [Form of 2014 Performance Incentive Plan NEO [removed: 3-Year] [added: Retentive] LTIP RSU Agreement (adopted [removed: 2018).](http://www.sec.gov/Archives/edgar/data/765880/000162828018005838/ex1023312018.htm)] [added: 2018).](http://www.sec.gov/Archives/edgar/data/765880/000155837015000716/hcp-20150331ex108280e48.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | May 3, 2018 | | |

Rewritten

| [removed: 10.11.4*] [added: 10.10.7*] | | | | | | [Form of 2014 Performance Incentive Plan NEO 3-Year [added: Performance-Based] LTIP [removed: RSU] [added: Unit] Agreement (adopted [removed: 2019).](http://www.sec.gov/Archives/edgar/data/765880/000162828019005690/ex1013312019.htm)] [added: 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10803312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: May 2, 2019] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11.5*] [added: 10.10.10*] | | | | | | [Form of 2014 Performance Incentive Plan NEO Retentive LTIP [removed: RSU] [added: Unit Award] Agreement (adopted [removed: 2018).](http://www.sec.gov/Archives/edgar/data/765880/000155837015000716/hcp-20150331ex108280e48.htm)] [added: 2023, for converted awards).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101103312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: May 3, 2018] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11.6*] [added: 10.10.4*] | | | | | | [Form of 2014 Performance Incentive Plan NEO [removed: Retentive LTIP RSU] [added: 3-Year Performance-Based Restricted Stock Unit] Agreement (adopted [removed: 2019).](http://www.sec.gov/Archives/edgar/data/765880/000162828019005690/ex1023312019.htm)] [added: 2022).](http://www.sec.gov/Archives/edgar/data/765880/000162828022012290/ex10103312022.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | May [removed: 2, 2019] [added: 4, 2022] | | |

Rewritten

| [removed: 10.11.7*] [added: 10.11.1*] | | | | | | [Form of [removed: 2014] [added: 2023] Performance Incentive Plan [removed: NEO 3-Year Performance-Based] [added: Non-NEO] Restricted Stock Unit [added: Award] Agreement (adopted [removed: 2022).](http://www.sec.gov/Archives/edgar/data/765880/000162828022012290/ex10103312022.htm)] [added: 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101303312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: May 4, 2022] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11.8*] [added: 10.11.2*] | | | | | | [Form of [removed: 2014] [added: 2023] Performance Incentive Plan Non-Employee Director [removed: RSU Agreement.](http://www.sec.gov/Archives/edgar/data/765880/000155837015000716/hcp-20150331ex109b060b7.htm)] [added: Restricted Stock Unit Award Agreement (adopted 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101403312023.htm)] | | | | | | Quarterly Report on Form 10-Q | | | | | | [removed: May 5, 2015] [added: April 28, 2023] | | |

Rewritten

| [removed: 10.11.9*†] [added: 10.10.5*] | | | | | | [Form of 2014 Performance Incentive Plan Non-NEO Restricted Stock Unit Award Agreement (adopted [removed: 2023).](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex1011912312022.htm)] [added: 2023).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101303312023.htm)] | | | | | | [added: Annual Report on Form 10‑K] | | | | | | [added: February 8, 2023] | | |

Rewritten

| 21.1† | | | | | | [Subsidiaries of the [removed: Company.](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex21112312022.htm)] [added: Company.](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex21112312023.htm)] | | | | | | | | | | | | | | |

Rewritten

| 23.1† | | | | | | [Consent of Independent Registered Public Accounting Firm—Deloitte & Touche [removed: LLP.](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex23112312022.htm)] [added: LLP.](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex23112312023.htm)] | | | | | | | | | | | | | | |

Rewritten

| 31.1† | | | | | | [Certification by Scott M. Brinker, Healthpeak’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule [removed: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex31112312022.htm)] [added: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex31112312023.htm)] | | | | | | | | | | | | | | |

Rewritten

| 31.2† | | | | | | [Certification by Peter A. Scott, Healthpeak’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule [removed: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex31212312022.htm)] [added: 13a‑14(a).](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex31212312023.htm)] | | | | | | | | | | | | | | |

Rewritten

| 32.1†† | | | | | | [Certification by Scott M. Brinker, Healthpeak’s Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a‑14(b) and 18 U.S.C. Section [removed: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex32112312022.htm).] [added: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex32112312023.htm).] | | | | | | | | | | | | | | |

Rewritten

| 32.2†† | | | | | | [Certification by Peter A. Scott, Healthpeak’s Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a‑14(b) and 18 U.S.C. Section [removed: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828023002794/ex32212312022.htm).] [added: 1350](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex32212312023.htm).] | | | | | | | | | | | | | | |

New in FY2023

| 2.1+ | | | | | | [Agreement and Plan of Merger, dated February 7, 2023, by and among Healthpeak Properties, Inc., New Healthpeak, Inc. and Healthpeak Merger Sub, Inc. (incorporated herein by reference to Exhibit 2.1 to Healthpeak’s filed).](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex2-1.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 2.2+ | | | | | | [Agreement and Plan of Merger, dated as of October 29, 2023, by and among Healthpeak Properties, Inc., DOC DR Holdco, LLC (formerly Alpine Sub, LLC), DOC DR, LLC (formerly Alpine OP Sub, LLC), Physicians Realty Trust and Physicians Realty L.P.](http://www.sec.gov/Archives/edgar/data/765880/000110465923112569/tm2329359d4_ex2-1.htm) | | | | | | Current Report on Form 8-K | | | | | | October 30, 2023 | | |

New in FY2023

| 3.1 | | | | | | [Articles of Amendment and Restatement of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, 2023.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-1.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 3.2 | | | | | | [Articles of Amendment of Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.) effective February 10, 2023.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex3-2.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 4.2 | | | | | | [Amended and Restated Indenture, dated as of February 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (amending and restating the Indenture, dated November 21, 2012, between Healthpeak and the trustee).](http://www.sec.gov/Archives/edgar/data/765880/000110465923018717/tm235984d25_ex4-6.htm) | | | | | | Registration Statement on Form S-3ASR (Registration No. 333‑269718) | | | | | | February 13, 2023 | | |

New in FY2023

| 4.2.9 | | | | | | [Fourteenth Supplemental Indenture, dated as of February 10, 2023, between Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex4-2.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 4.2.10 | | | | | | [Fifteenth Supplemental Indenture, dated as of May 10, 2023, among Healthpeak OP, LLC, as issuer, Healthpeak Properties, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-1.htm) | | | | | | Current Report on Form 8-K | | | | | | May 10, 2023 | | |

New in FY2023

| 4.13 | | | | | | [Form of 5.250% Senior Notes due 2032, including the form of Notation of Guarantee.](http://www.sec.gov/Archives/edgar/data/765880/000110465923058454/tm2315206d1_ex4-2.htm) | | | | | | Current Report on Form 8-K | | | | | | May 10, 2023 | | |

New in FY2023

| 10.1 | | | | | | [Operating Agreement of Healthpeak OP, LLC, dated as of February 10, 2023.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-1.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 10.2 | | | | | | [Omnibus Assignment, Assumption and Amendment, dated February 7, 2023 by and between Healthpeak OP, LLC (formerly Healthpeak Properties, Inc.) and Healthpeak Properties, Inc. (formerly New Healthpeak, Inc.).](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-4.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 10.3.1 | | | | | | [Consent and Amendment No. 1 to Second Amended and Restated Credit Agreement, dated as of February 10, 2023, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., the lenders listed therein and Bank of America, N.A., as administrative agent.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-2.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 10.4.1 | | | | | | [Consent and Amendment No. 1 to Term Loan Agreement, dated as of February 10, 2023, by and among Healthpeak OP, LLC, Healthpeak Properties, Inc., the lenders listed therein and Bank of America, N.A., as administrative agent.](http://www.sec.gov/Archives/edgar/data/765880/000110465923018524/tm235984d2_ex10-3.htm) | | | | | | Current Report on Form 8-K12B | | | | | | February 10, 2023 | | |

New in FY2023

| 10.10.8* | | | | | | [Form of 2014 Performance Incentive Plan NEO Retentive LTIP Unit Agreement (adopted 2023, for converted 2021 and 2022 LTIP awards).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex10903312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

New in FY2023

| 10.10.9* | | | | | | [Form of 2014 Performance Incentive Plan NEO 3-Year Performance-Based LTIP Unit Agreement (adopted 2023, for converted 2021 and 2022 LTIP awards).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101003312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

New in FY2023

| 10.10.11* | | | | | | [Form of 2014 Performance Incentive Plan Non-NEO LTIP Unit Award Agreement (adopted 2023, for converted awards).](http://www.sec.gov/Archives/edgar/data/765880/000162828023014190/ex101203312023.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | April 28, 2023 | | |

New in FY2023

| 10.11* | | | | | | [Healthpeak Properties, Inc. 2023 Performance Incentive Plan.](http://www.sec.gov/Archives/edgar/data/765880/000110465923051395/tm2313656d1_ex10-1.htm) | | | | | | Current Report on Form 8-K | | | | | | April 27, 2023 | | |

New in FY2023

| 22.1† | | | | | | [List of Issuers of Guaranteed Securities.](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex22112312023.htm) | | | | | | | | | | | | | | |

New in FY2023

| 97.1† | | | | | | [Policy Regarding the Recoupment of Certain Compensation Payments.](https://www.sec.gov/Archives/edgar/data/765880/000162828024004094/ex97112312023.htm) | | | | | | | | | | | | | | |

New in FY2023

\+ Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2).

Dropped from FY2022

| 10.3.1 | | | | | | [Amendment No. 1 to At-the-Market Equity Offering Sales Agreement, dated May 13, 2021, among Healthpeak and the sales agents, forward sellers and forward purchasers referred to therein.](http://www.sec.gov/Archives/edgar/data/765880/000162828021015545/ex10106302021.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | August 4, 2021 | | |

Dropped from FY2022

| 10.8* | | | | | | [Release Agreement for Thomas M. Herzog, dated October 6, 2022.](http://www.sec.gov/Archives/edgar/data/765880/000119312522258944/d335330dex101.htm) | | | | | | Current Report on Form 8‑K | | | | | | October 6, 2022 | | |

Dropped from FY2022

| 10.9* | | | | | | [Release Agreement for Troy E. McHenry, dated November 1, 2022.](http://www.sec.gov/Archives/edgar/data/765880/000162828022027566/ex10109302022.htm) | | | | | | Current Report on Form 8‑K | | | | | | November 1, 2022 | | |

Dropped from FY2022

| 10.10* | | | | | | [2006 Performance Incentive Plan, as amended and restated.](http://www.sec.gov/Archives/edgar/data/765880/000104746909002429/a2191338zdef14a.htm) | | | | | | Annex 2 to HCP’s Proxy Statement | | | | | | March 10, 2009 | | |

Dropped from FY2022

| 10.10.1* | | | | | | [Form of Employee 2006 Performance Incentive Plan Nonqualified Stock Option Agreement.](http://www.sec.gov/Archives/edgar/data/765880/000110465912030975/a12-8339_1ex10d4.htm) | | | | | | Quarterly Report on Form 10‑Q | | | | | | May 1, 2012 | | |

Dropped from FY2022

| 10.14 | | | | | | [Amended and Restated Limited Liability Company Agreement of HCPI/Utah, LLC, dated as of January 20, 1999.](http://www.sec.gov/Archives/edgar/data/765880/0000765880-99-000021.txt) | | | | | | Annual Report on Form 10‑K | | | | | | March 29, 1999 | | |

Dropped from FY2022

| 10.14.1 | | | | | | [Amendments No. 1-9 to Amended and Restated Limited Liability Company Agreement of HCPI/Utah, LLC, dated as of January 20, 1999.](http://www.sec.gov/Archives/edgar/data/765880/000162828018001552/ex109112312017.htm) | | | | | | Annual Report on Form 10‑K | | | | | | February 13, 2018 | | |

Dropped from FY2022

| 10.14.2 | | | | | | [Tax Matters Amendment to Amended and Restated Limited Liability Company Agreement of HCPI/Utah, LLC, effective as of December 31, 2018.](http://www.sec.gov/Archives/edgar/data/765880/000162828019001407/ex109212312018.htm) | | | | | | Annual Report on Form 10‑K | | | | | | February 14, 2019 | | |

Dropped from FY2022

| 10.15 | | | | | | [Amended and Restated Limited Liability Company Agreement of HCPI/Utah II, LLC, dated as of August 17, 2001, as amended.](http://www.sec.gov/Archives/edgar/data/765880/000110465912076683/a12-26100_2ex10d1.htm) | | | | | | Current Report on Form 8‑K | | | | | | November 9, 2012 | | |

Dropped from FY2022

| 10.15.1 | | | | | | [Tax Matters Amendment to Amended and Restated Limited Liability Company Agreement of HCPI/Utah II, LLC, effective as of December 31, 2018.](http://www.sec.gov/Archives/edgar/data/765880/000162828019001407/ex1010112312018.htm) | | | | | | Annual Report on Form 10‑K | | | | | | February 14, 2019 | | |

Dropped from FY2022

| 10.16 | | | | | | [Amended and Restated Limited Liability Company Agreement of HCPI/Tennessee, LLC, dated as of October 2, 2003.](http://www.sec.gov/Archives/edgar/data/765880/000119312503078679/dex1028.htm) | | | | | | Quarterly Report on Form 10‑Q | | | | | | November 12, 2003 | | |

Dropped from FY2022

| 10.16.1 | | | | | | [Amendment No. 1 to Amended and Restated Limited Liability Company Agreement of HCPI/Tennessee, LLC, dated as of September 29, 2004.](http://www.sec.gov/Archives/edgar/data/765880/000119312504189646/dex1037.htm) | | | | | | Quarterly Report on Form 10‑Q | | | | | | November 8, 2004 | | |

Dropped from FY2022

| 10.16.2 | | | | | | [Amendment No. 2 to Amended and Restated Limited Liability Company Agreement of HCPI/Tennessee, LLC, dated as of October 27, 2004.](http://www.sec.gov/Archives/edgar/data/765880/000119312505049849/dex1043.htm) | | | | | | Annual Report on Form 10‑K | | | | | | March 15, 2005 | | |

Dropped from FY2022

| 10.16.3 | | | | | | [Amendment No. 3 to Amended and Restated Limited Liability Company Agreement of HCPI/Tennessee, LLC and New Member Joinder Agreement, dated as of October 19, 2005, by and among Healthpeak, HCPI/Tennessee, LLC and A. Daniel Weyland.](http://www.sec.gov/Archives/edgar/data/765880/000110465905051311/a05-18450_1ex10d14d3.htm) | | | | | | Quarterly Report on Form 10‑Q | | | | | | November 1, 2005 | | |

Dropped from FY2022

| 10.16.4 | | | | | | [Amendment No. 4 to Amended and Restated Limited Liability Company Agreement of HCPI/Tennessee, LLC, effective as of January 1, 2007.](http://www.sec.gov/Archives/edgar/data/765880/000104746908001116/a2182240zex-10_124.htm) | | | | | | Annual Report on Form 10‑K, as amended | | | | | | February 12, 2008 | | |

Dropped from FY2022

| 10.16.5 | | | | | | [Tax Matters Amendment to Amended and Restated Limited Liability Company Agreement of HCPI/Tennessee, LLC, effective as of December 31, 2018.](http://www.sec.gov/Archives/edgar/data/765880/000162828019001407/ex1011512312018.htm) | | | | | | Annual Report on Form 10-K | | | | | | February 14, 2019 | | |

Dropped from FY2022

| 10.17 | | | | | | [Amended and Restated Limited Liability Company Agreement of HCP DR MCD, LLC, dated as of February 9, 2007.](http://www.sec.gov/Archives/edgar/data/765880/000110465912026870/a12-9268_1ex10d1.htm) | | | | | | Current Report on Form 8-K | | | | | | April 20, 2012 | | |

Dropped from FY2022

| 10.17.1 | | | | | | [Tax Matters Amendment to Amended and Restated Limited Liability Company Agreement of HCP DR MCD, LLC, effective as of December 31, 2018.](http://www.sec.gov/Archives/edgar/data/765880/000162828019001407/ex1012112312018.htm) | | | | | | Annual Report on Form 10-K | | | | | | February 14, 2019 | | |

Dropped from FY2022

| 10.18 | | | | | | [Amended and Restated Limited Liability Company Agreement of HCP DR California II, LLC, dated as of June 1, 2014.](http://www.sec.gov/Archives/edgar/data/765880/000110465914056632/a14-13936_1ex10d12.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | August 5, 2014 | | |

Dropped from FY2022

| 10.18.1 | | | | | | [Tax Matters Amendment to Amended and Restated Limited Liability Company Agreement of HCP DR California II, LLC, effective as of December 31, 2018.](http://www.sec.gov/Archives/edgar/data/765880/000162828019001407/ex1013112312018.htm) | | | | | | Annual Report on Form 10-K | | | | | | February 14, 2019 | | |

Dropped from FY2022

| 10.19 | | | | | | [Amended and Restated Limited Liability Company Agreement of HCP DR California III, LLC, dated as of May 1, 2019.](http://www.sec.gov/Archives/edgar/data/765880/000162828019009779/ex1016302019.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | August 1, 2019 | | |

Dropped from FY2022

| 10.19.1 | | | | | | [Amendment No. 1 to Amended and Restated Limited Liability Company Agreement of HCP DR California III, LLC, dated as of April 30, 2021.](http://www.sec.gov/Archives/edgar/data/765880/000162828021021470/ex10209302021.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | November 3, 2021 | | |

Dropped from FY2022

| 10.20 | | | | | | [Second Amended and Restated Limited Liability Company Agreement of SH DR California IV, LLC, dated as of July 18, 2019.](http://www.sec.gov/Archives/edgar/data/765880/000162828019012968/ex1019302019.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | October 31, 2019 | | |

Dropped from FY2022

| 10.20.1 | | | | | | [Amendment No. 1 to Second Amended and Restated Limited Liability Company Agreement of SH DR California IV, LLC, dated as of April 30, 2021.](http://www.sec.gov/Archives/edgar/data/765880/000162828021021470/ex10309302021.htm) | | | | | | Quarterly Report on Form 10-Q | | | | | | November 3, 2021 | | |

Item 16. Form 10-K Summary

10 rewritten, 3 added, 1 removed, 16 unchanged

Read the full itemFY2023 item · filed February 9, 2024FY2022 item · filed February 8, 2023

Rewritten

Dated: February [removed: 8, 2023][added: 9, 2024]

Rewritten

| | | | Healthpeak Properties, Inc. [removed: (Registrant)] | | |

Rewritten

| /s/ SCOTT M. BRINKER | | | | | | President and Chief Executive Officer, Director | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ PETER A. SCOTT | | | | | | Chief Financial Officer | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ SHAWN G. JOHNSTON | | | | | | Executive Vice President and Chief Accounting Officer | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ KATHERINE M. SANDSTROM | | | | | | [removed: Vice] Chair of the Board | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ CHRISTINE N. GARVEY | | | | | | Director | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ R. KENT GRIFFIN, JR. | | | | | | Director | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ DAVID B. HENRY | | | | | | Director | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

Rewritten

| /s/ SARA GROOTWASSINK LEWIS | | | | | | Director | | | | | | February [removed: 8, 2023] [added: 9, 2024] | | |

New in FY2023

| /s/ BRIAN G. CARTWRIGHT | | | | | | Director | | | | | | February 9, 2024 | | |

New in FY2023

| /s/ JAMES B. CONNOR | | | | | | Director | | | | | | February 9, 2024 | | |

New in FY2023

| James B. Connor | | | | | | | | | | | | | | |

Dropped from FY2022

| /s/ BRIAN G. CARTWRIGHT | | | | | | Chairman of the Board | | | | | | February 8, 2023 | | |